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Currently, the most popular method of ischemic stroke treatment is intravenous 
administration of thrombolytics like alteplase.  Once administered, the rate of 
thrombolytic delivery to a clot in a fully occluded vessel is limited by the slow process of 
diffusion.  This is problematic as increased duration of the hypoxic state due to a 
thrombus or embolus increases the likelihood of severe disability and death. 
The transport of the drug could be improved by inducing fluid flow within the 
blocked vessel.  This could be accomplished by utilizing a methodology invented by 
Pulse Therapeutics.  Ferroparticles are administered along with the thrombolytic, and a 
rotating magnetic field with a gradient is applied to the affected region of the stroke 
victim’s brain.  The presence of the magnetic field causes the ferroparticles to aggregate. 
Its rotation causes the aggregates to rotate, and its gradient causes the rotating aggregates 
to produce a net unidirectional flow within the blocked vessel. 
A general analytical model describing this process is developed to assist 
prediction of the qualitative effect of changing various system parameters like the 
magnetic field strength or rotation rate.  Increasingly complex two-dimensional models 
 vi 
are developed and computationally analyzed to quantitatively predict the resulting 
velocity profile in a blocked vessel. 
Computational analyses were also performed to simulate the diffusion-limited and 
magnetically-enhanced transport of thrombolytics.  As anticipated, utilizing the rotating 
magnetic field with a gradient significantly improves transport in a blocked vessel. 
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Chapter 1:  Introduction 
1.1 STROKE 
Stroke is the fourth leading cause of death in the United States [Corbyn (2014)].  
With a mortality rate of 17 percent, stroke accounts for approximately one out of every 
eighteen fatalities or 134,000 total fatalities each year [Roger et al. (2012)].  Stroke 
survivors have a roughly 75 percent chance of moderate to severe disability [Kwon et al. 
(2004)].  On average, the lifetime cost of a first stroke per survivor is approximately 
$140,000 [Roger et al. (2012)]. 
Strokes result in reduced blood flow to a region of the brain.  Some are classified 
as hemorrhagic and are due to ruptured blood vessels.  Eight-seven percent of strokes, 
however, are classified as ischemic [Roger et al. (2012)], meaning they result from a 
blockage of blood flow to the brain due to a thrombus or embolus.  A thrombus, or blood 
clot, forms by aggregation of blood platelets and fibrin usually consequent to an injury to 
a blood vessel [Furie and Furie (2008)].   
The endothelium, which lines the interior of blood vessels, typically ensures that 
blood vessel walls are not conducive to thrombogenesis or clot formation.  When the 
endothelium is damaged, the subendothelial matrix, which contains collagen and tissue 
factor, is exposed to the circulating blood. This leads to the formation of a plug at the 
injury site as blood platelets then bind directly to collagen.  Simultaneously, coagulation 
factor VII in the blood plasma comes into contact with tissue factor to form an activated 
complex, which can bind to coagulation factor X, activating it.  The activated factor X 
complexes with its cofactor, activated factor V, to yield the prothrombinase complex that 
activates prothrombin to thrombin.  Thrombin performs multiple important functions.  It 
amplifies the coagulation pathway by activating coagulation factors V, VIII, and XI, 
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converts fibrinogen into insoluble fibrin strands, and activates coagulation factor XIII to 
crosslink the fibrin strands [Furie and Furie (2008)].  The crosslinked fibrin mesh 
strengthens the platelet plug and stabilizes the thrombus. 
An embolus is typically a detached thrombus or portion thereof, which can 
become lodged far from the original clot, clogging a blood vessel.  The blocked blood 
flow due to either a thrombus or embolus can result in hypoxia, or oxygen deprivation of 
cells, and finally cell and tissue death from lack of oxygen.  Disabilities, varying based on 
the location of the clot and affected cells, arise as brain cells die due to prolonged oxygen 
deprivation as shown in Figure 1.1 [Corbyn (2014)].  Increased duration of the hypoxic 
state increases the permanency and severity of these disabilities as well as increasing the 
chance of death. 
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Figure 1.1:  Schematic of ischemic and hemorrhagic strokes with functions affected for 
different areas of the brain [Corbyn (2014)]. 
1.2 CURRENT METHODS OF STROKE TREATMENT 
1.2.1 Mechanical Thrombectomy 
Several methods have been developed to deal with this widespread and serious 
health problem.  Mechanical thrombectomy, also known as endovascular therapy, 
mechanical intervention, and embolectomy, involves using a device to physically remove 
a thrombus.  While several different devices exist, their basic components are quite 
similar.  Each device includes a microcatheter through which the rest of the device is 
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transported to the thrombus, a wire or system of wires to physically ensnare the 
thrombus, and a balloon guide catheter, which inflates proximal to, or positioned before, 
the thrombus, to control and suspend blood flow as the clot is being removed or 
withdrawn.  Aspiration, or suction, is applied to the balloon guide catheter, to ensure all 
clot debris is removed from the blood vessel and cannot act as emboli.  The balloon guide 
catheter subsequently deflates to re-establish flow [Gobin et al. (2004), Langer et al. 
(2009), Machi et al. (2011)]. 
The most obvious difference between the various devices is the form of the wire 
or wires used to withdraw the clot.  MERCI X5, X6 and L5 devices use a memory shaped 
nitinol wire that remains in its straight configuration within the microcatheter.  When 
deployed from the microcatheter, however, it returns to its previously set shape of helical 
loops as shown in Figure 1.2 [Smith et al. (2008)].  The microcatheter must first 
transverse the thrombus. Then, the first two or three loops of the nitinol wire are 
delivered distal to, or beyond, the thrombus.  These helical loops are pulled back until 
they contact the thrombus at which point further loops are deployed into the clot.  The 




Figure 1.2: Depiction of the L5 and X6 MERCI devices removing a thrombus without 
balloon guide catheter [Smith et al. (2008)]. 
The Solitaire FR device [Machi et al. (2011)], shown in Figure 1.3, uses a nitinol 
wire mesh that acts as a stent, expanding to fill the blood vessel.  As in the MERCI 
devices, the microcatheter must first transverse the thrombus. The stent retriever is 
positioned such that it bridges the proximal and distal ends of the thrombus. Next, the 
microcatheter sheath is retracted allowing the stent to expand before being drawn back to 
the balloon guide catheter. 
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Figure 1.3: Schematic of Solitaire FR device with long stent retriever [Machi et al. 
(2011)]. 
The Penumbra system [Langer et al. (2009)], shown in Figure 1.4, first attempts 
to remove the thrombus by aspiration using its separator. In this case, suction is applied 
to a reperfusion catheter instead of the balloon guide catheter.   If residual thrombus still 
remains after aspiration, then a wire mesh, referred to as a thrombus removal ring, is used 
to remove the thrombus directly, embedding at least a centimeter into the proximal end of 
the thrombus.  Subsequently, the reperfusion catheter is advanced until it is also 
embedded into the thrombus.  Finally, as in the other systems, the thrombus removal ring 






Figure 1.4: Penumbra system including reperfusion catheters and separators (left) and 
thrombus removal ring (right) [Langer et al. (2009)]. 
Unfortunately, the use of these devices requires a trained doctor to insert a 
catheter into the femoral artery near the groin and then thread the catheter up to the 
blockage, or occlusion.  In the event that a qualified physician is unavailable, the 
treatment becomes impractical and would not be performed at all.  In addition, the 
operation should be performed within 6 to 8 hours of stroke onset [Broderick (2009), 
Powers et al. (2015)], and the thrombus needs to be imaged and located first. 
1.2.2 Ultrasound 
Another potential option for ischemic stroke treatment is thrombus dissolution via 
ultrasound.  This method is known as both sonolysis and sonothrombolysis.  The exact 
mechanism of treatment varies but is often similar to that used in diagnostics to produce 
ultrasound images.  While a low intensity diagnostic ultrasound beam is used to cause 
targeted microbubbles to oscillate, high intensity ultrasound pressure instead causes the 
targeted microbubbles to react violently: bursting and releasing energy that can be 
utilized to destroy a thrombus.  Even at lower intensity, the expanding and contracting 
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microbubbles can deform and erode a thrombus [Chen X. et al. (2014), Roos et al. 
(2014)].  At present, however, sonolysis is unused for stroke treatment outside of research 
unless paired with another method of stroke treatment.  Cerevast Therapeutics is 
developing an ultrasound emitting headset apparatus that could be used in conjunction 
with intravenous administration of microbubbles without extensive specialized training 
[Alleman et al. (2013)]. 
Ultrasound’s role in typical stroke treatment is generally more preventative. 
Stroke survivors and individuals otherwise at high risk for stroke may undergo a carotid 
ultrasound to image the carotid arteries in order to detect blood clots or plaque buildup 
due to atherosclerosis.  Significant plaque buildup can lead to a stroke since the plaque 
can directly reduce blood flow to the brain or a piece of it may break off to form an 
embolus.  If the ultrasound identifies a problem, the thrombus or plaque may be 
surgically removed or a carotid artery stent may be inserted [Hill et al. (2012)]. 
Ultrasound may also be used as a low cost, low risk, readily available imaging 
tool in current stroke victims, but magnetic resonance imaging (MRI) or computed 
tomography (CT) is typically performed first [Huibers et al. (2015)].  
1.2.3 Antithrombotic Treatment 
The most common method of dealing with thrombi, however, is the use of 
antithrombotics, or drugs that destroy thrombi or prevent their formation.  
Antithrombotics include antiplatelet drugs like aspirin, which inhibit platelet aggregation, 
anticoagulants like heparin, which inhibit the coagulation pathway, and thrombolytics, 
which dissolve existing thrombi.  Thrombolytics are the primary drugs used to treat 
strokes, although they are often used in conjunction with an anticoagulant or antiplatelet 
drug. 
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In addition, administration of thrombolytics may also accompany sonolysis in a 
treatment invariably referred to as sonothrombolysis [Roos et al. (2014)].  In this case, -
thrombo- refers to the thrombolytic doing the lysing, or destroying, instead of to the 
thrombus being destroyed.  Such sonothrombolysis may be performed with or without 
microbubbles.  In the absence of the microbubbles, the ultrasound energy produces 
pressure waves in the blocked artery. This improves delivery of the thrombolytic to the 
clot as well as penetration of the thrombolytic into the clot [Rubiera and Alexandrov 
(2010)]. 
Mechanical thrombectomy may also be used following intravenous thrombolytic 
therapy [Broderick (2009)].  According to the American Heart Association and American 
Stroke Association’s latest guidelines, mechanical thrombectomy should be attempted 
following thrombolytic treatment regardless of patient response if still within 6 hours of 
stroke onset [Powers et al. (2015)]. 
The EKOS ultrasound-assisted catheter-directed thrombolysis system, though 
currently lacking FDA approval for stroke treatment, actually combines all three methods 
of treatment as it delivers thrombolytic directly to a blocked vessel while emitting 
ultrasound to induce pressure waves [McCabe et al. (2015)].   
1.3 THROMBOLYTICS 
Thrombolytics are drugs which aim to break down existing blood clots.  
Streptokinase (SK), urokinase, and tissue plasminogen activator (tPA) are three 
commonly used thrombolytics that are termed fibrinolytics, which break down the fibrin 
in a clot.  Streptokinase, urokinase and tPA all function by activating plasminogen, a 
zymogen that is produced by the liver [Mehta and Shapiro (2008)] and comprises part of 
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thrombi. The active enzyme, plasmin, then directly breaks down the blood clots by 
cleaving the fibrin mesh holding the clot together [Baker (2003)]   
Streptokinase is produced by streptococci bacteria.  In order to activate 
plasminogen, SK complexes with it in a 1:1 stoichiometric ratio [Lottenberg et al. (1992), 
Runge et al. (1989), Verstraete (1987)].  Urokinase is an active human enzyme that was 
originally isolated from urine, although it can be found in different physiological 
locations including kidney cells [White et al. (1966)]. As an active enzyme, urokinase 
can directly convert plasminogen into plasmin by cleaving a specific peptide bond 
without forming a complex.  tPA is a human protein that is secreted by various tissues, 
including the endothelium.  tPA and plasminogen react according to Michaelis-Menten 
enzyme-substrate kinetics.  Streptokinase lacks fibrin selectivity, but tPA binds fibrin, 
which catalyzes the reaction with plasminogen when bound [Runge et al. (1989)]. 
Streptokinase, urokinase, and tPA have all been FDA approved thrombolytics at 
one time.  Urokinase was most recently re-approved by the FDA in 2002 for treatment of 
pulmonary emboli, or for clots obstructing blood flow to the lungs, but not ischemic 
stroke.  At that time, urokinase was produced by Abbott Laboratories under the brand 
name Abbokinase.  Subsequently, Microbix acquired the rights to Abbokinase and re-
branded it as Kinlytic.  Unfortunately, Microbix’s lack of an approved manufacturing 
facility has kept urokinase unavailable to patients since 2009 [Microbix]. 
Streptokinase production under the brand name Streptase has been discontinued in 
the US, however, it was once FDA approved for treatment of myocardial infarctions, 
commonly known as heart attacks.  Streptokinase is still marketed globally for treatment 
of heart attack, pulmonary embolism, and deep vein thrombosis.  It is sold under a variety 
of names, most notably Streptase, which is produced by CSL Behring for use in 
Argentina, Australia, Bosnia & Herzegovina, Brazil, Bulgaria, China, Denmark, 
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Germany, Hong Kong, Hungary, Indonesia, Israel, the Netherlands, New Zealand, 
Poland, Portugal, Serbia, Spain, Sweden, Taiwan, and the United Kingdom, by Sanofi 
Aventis for use in Bangladesh, India, and Taiwan, and by various other companies for 
use in Colombia, Croatia, Egypt, Greece, Lebanon, Malta, South Africa, and Turkey.  It 
is sold under other names in Georgia, Lithuania, Mexico, Myanmar, Pakistan, the 
Philippines, and Vietnam [Drugs.com].  A recombinant form of streptokinase, known as 
Heberkinasa, or Heberkinase, is manufactured by Heber Biotech and sold throughout 
much of Latin America including Cuba, Ecuador, and Venezuela [Hermentin et al. 
(2005)].  Indeed, streptokinase remains the most commonly used thrombolytic 
worldwide.  This is likely due, in large part, to its low cost.  Streptokinase is cheaper than 
urokinase and much cheaper than tPA.  Streptokinase is also the only thrombolytic on the 
World Health Organization’s List of Essential Medicines, which is meant to include the 
most important medications necessary in any basic healthcare system, prioritizing 
efficacy, safety and cost-effectiveness [World Health Organization]. 
The brands of tPA that are commercially available in the United States today are 
recombinant tPA’s.  Tenecteplase, produced under the brand name TNKase by 
Genentech, has higher fibrin specificity than native tPA [Genentech], while reteplase, 
produced under the brand name Retavase by Chiesi USA, has lower fibrin specificity 
than native tPA [Chiesi USA].  Both tenecteplase and reteplase are FDA approved for 
treatment of myocardial infarction but not ischemic stroke.  Alteplase, produced under 
the brand name Activase by Genentech, is in fact the only thrombolytic FDA approved 
for treating ischemic stroke [Food and Drug Administration].  It should be administered 
intravenously within three hours of stroke onset [Donnan et al. (2003)].  Alteplase is 
broadly applicable and is also approved for treatment of both myocardial infarctions and 
pulmonary emboli [Genentech]. 
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The decision by the FDA to not approve streptokinase for ischemic stroke 
treatment was quite controversial. The decision was likely based off the three intravenous 
streptokinase trials: Australian Streptokinase Trial (ASK) and the two Multicenter Acute 
Stroke Trials: European (MAST-E) and Italian (MAST-I).  Each of the trials was 
terminated prematurely due to excess mortality due to hemorrhaging.  All three of these 
trials are widely believed to have been flawed in their design, however.  In the 
streptokinase ischemic stroke trials, the treatment time window and the administered 
dosage relative to the cardiac dosage were larger than in tPA trials, and streptokinase was 
administered along with aspirin and/or heparin [Broderick and Hacke (2002), Cornu et al. 
(2000), Jaillard et al. (1999)].  Due to the premature end to those trials, these issues were 
left uncorrected.  Despite all these experimental design flaws promoting the risk of 
hemorrhaging, the ASK trial still found a trend toward patient benefit when focusing only 
on the sub-set of patients treated within three hours [Broderick and Hacke (2002)], which 
is the same as the current recommended time window for administration of alteplase. 
 The issue with intravenous administration of any thrombolytic, including 
alteplase, is that its delivery to a thrombus in a fully occluded vessel is limited by its rate 
of diffusion [Clements and Bonnecaze (2013), Piebalgs and Xu (2015)].  Hospitals strive 
to minimize their door-to-needle time, or the time between patients entering the hospital 
and being administered the thrombolytic.  This serves to maximize the percentage of 
stroke patients able to receive IV thrombolytic treatment within the typically required 3 
to 4.5 hour time window [Maulaz et al. (2009)].  Once the drug has been administered, 
however, the time required for it to reach the clot and react is controlled by convection, 
diffusion, and reaction kinetics.  The delay in thrombolytic delivery to the clot due to 
slow diffusion in a completely blocked artery could easily prove fatal.  Unfortunately, the 
simplest method of improving diffusion rate by increasing the concentration of 
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thrombolytic is impractical since elevated concentration leads to high risk of 
hemorrhaging and other bleeding complications [Gardell (1993), Van de Werf (1999)]. 
 In intra-arterial thrombolytic stroke treatment, the thrombolytic is delivered 
directly into the occluded vessel at the clot within six hours of stroke onset.  This 
eliminates the time delay associated with the drug’s diffusion through the blocked vessel 
to the thrombus.  In addition, since the thrombolytic is delivered locally, systemic 
fibrinolysis is avoided, reducing the chance of bleeding complications arising.  Like 
mechanical thrombectomy, however, intra-arterial stroke treatment requires a trained 
doctor to perform the procedure after the thrombus has been located and imaged [Mattle 
(2007)]. 
1.4 MECHANISM FOR MAGNETICALLY-ASSISTED DELIVERY OF THROMBOLYTICS 
Pulse Therapeutics has invented a method for rapidly delivering thrombolytics 
that can be easily performed by a nurse [Creighton (2012), Creighton (2013), Creighton 
(2014)].  The apparatus associated with this delivery method is a permanent magnet that 
uses a two-motor system so that it can rotate in any plane.  It generates a rotating 
magnetic field with a gradient and applies it to the affected area of the stroke victim’s 
brain.  The affected area is typically determined from a CT scan.  Approximately 0.1 
micron diameter ferroparticles added to the IV during thrombolytic administration 
interact with the magnetic field, inducing a flow within the occluded vessel (Figure 1.5). 
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Figure 1.5: Schematic of Pulse Therapeutic’s method for treating ischemic strokes by 
adding ferroparticles during the thrombolytic’s IV administration and using 
a specially designed apparatus to apply a rotating magnetic field with a 
gradient to the affected area of the brain [Creighton (2014)]. 
In the presence of a magnetic field, ferroparticles aggregate into chains, which 
experience a torque and subsequent rotation in a rotating magnetic field.  The hypothesis 
is that the rotation of the particle aggregates is the immediate cause of the induced fluid 
flow in the blocked vessel, re-establishing convective transport and eliminating the 
problem of slow diffusive drug delivery. 
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1.4 DISSERTATION OUTLINE 
In the following chapters, I will discuss thrombolytic delivery and models thereof 
for both the standard diffusion-limited intravenous method and Pulse Therapeutic’s 
magnetically-enhanced method. 
In Chapter 2, diffusion-limited thrombolytic delivery is studied computationally.  
A computational model simulating streptokinase and tPA’s transport and reaction with 
plasminogen in the occluded vessel and the unblocked vessel from which it branches is 
developed.  The length and diameter of the blocked vessel, the flowrate in the unblocked 
vessel, and the angle between the two vessels are all treated as system variables.  The 
concentration profiles for the thrombolytics and plasminogen one hour after the start of 
the intravenous treatment are predicted.  The amount of the drug delivered to the 
thrombus is also simulated transiently. 
In Chapter 3, a general analytical model for Pulse Therapeutic’s method of 
magnetically-assisted thrombolytic delivery is setup in which the ferroparticles are 
assumed to have already aggregated into chains in response to the presence of the 
magnetic field.  Equations describing the rotation of the aggregates are derived by 
balancing the magnetic and hydrodynamic torques acting on the aggregates.  The fluid 
flow is described according to conservation of mass and linear momentum.  The 
suspension dynamics of the fluid flow are linked to the particle dynamics of the 
aggregates’ rotation by the antisymmetric stress and magnetic torque resulting from the 
body couple of the applied magnetic field acting on the magnetized particles. 
In Chapter 4, the model is simplified to a two-dimensional model for the 
theoretical case where the source of the magnetic field is located at the occluded vessel 
and the size of the aggregates is fixed with respect to both space and time. 
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In Chapters 5 and 6 the two-dimensional model is improved. In Chapter 5, the 
model is made to account for the magnetic field source’s displacement from the occluded 
vessel.  This corresponds with Pulse Therapeutic’s magnet apparatus rotating beside the 
patient’s head instead of inside it.  In Chapter 6, the model is further improved to account 
for the aggregate size being functionally related to the shear and to the applied magnetic 
field’s strength and rotation rate.  The aggregates grow in response to increasing 
magnetic field strength and can be torn apart by increasing shear or H-field rotation rate.   
In Chapter 7, the magnetically-enhanced transport of a non-reactive species in an 
occluded vessel is computationally studied.  Finally, in Chapter 8, key conclusions, 
drawn from the model and simulations, are presented along with recommendations for 
future work on this topic. 
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Chapter 2: Diffusion-Limited Thrombolytic Delivery∗ 
2.1 INTRODUCTION 
Stroke is the fourth leading cause of death in the United States accounting for 
approximately one out of every eighteen or 134,000 total fatalities each year [Corbyn 
(2014), Roger et al. (2012)].  Stroke has a mortality rate of over 17 percent, and the 
survivors have about a 75 percent chance of moderate to severe disability [Kwon et al. 
(2004), Roger et al. (2012)].  Some strokes are classified as hemorrhagic and are due to 
ruptured blood vessels.  Eighty-seven percent of all strokes though are ischemic [Roger et 
al. (2012)], caused by a blockage of blood flow and starvation of oxygen to the brain due 
to a thrombus or embolus. 
Thrombolytics are an important class of pharmaceutical treatment that aims to 
break down existing blood clots, thereby eliminating them.  Most thrombolytics can also 
be termed fibrinolytics, which specifically break down the fibrin in a clot.  Streptokinase 
(SK) and tissue plasminogen activator (tPA) are two commonly used fibrinolytics.  Both 
of these proteins activate plasminogen, which is part of the thrombi, to plasmin which 
cleaves fibrin mesh and breaks down blood clots [Baker (2003)].  
Despite the ideal placement of plasminogen in the clot, timely delivery of a 
thrombolytic remains difficult, particularly in more severe strokes.  As a thrombus blocks 
off blood flow, convective transport of the drug to the clot decreases.  If the blood vessel 
completely clogs so there is no blood flow past the thrombus or embolus, convection can 
only transport the drug to the branch point of the occluded vessel.  Subsequent delivery to 
                                                 
∗ Much of this chapter has appeared in Clements M. and R. Bonnecaze, "Diffusion limited delivery of 
streptokinase and tPA to a thrombus," Cardiovascular Engineering and Technology 4 (4), 364-373 (2013). 
 
Dr. Bonnecaze contributed to this publication by advising on the research and critiquing the article. 
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the clot must be achieved solely by diffusion in the blocked vessel.  This is especially 
problematic because diffusion is much slower than forced convection; the resulting time 
lag could easily be fatal. 
For effective treatment, an amount of thrombolytic sufficient to dissolve the clot 
must be delivered to the thrombus as soon as possible before a large number of brain cells 
die from oxygen and nutrient deprivation.  Typically hospitals adhere to a 3 to 4.5 hour 
treatment window for thrombolytics like tPA [Maulaz et al. (2009)].  More than 3 hours 
after the initial presentation of stroke symptoms, most physicians opt not to administer a 
thrombolytic since the probability of the treatment saving the life of the patient is very 
small and the risk of unwanted side effects such as hemorrhaging increases.  Hospitals 
have set up rigorous protocols to reduce their door-to-needle time, or the time lost 
between the patient entering the hospital and having the thrombolytic administered to 
them.  This is beneficial, but once injected the time needed for the thrombolytic to reach 
and react with the thrombus is controlled by the convection, diffusion, and reaction in the 
bloodstream and the thrombus [Donnan et al. (2003), Gardell (1993), Runge et al. (1989), 
Van de Werf (1999), Verstraete (1987)].   
The reaction of streptokinase and tPA with plasminogen is computationally 
studied as they convect and diffuse from the bulk flow in the neighboring unblocked 
vessel through the occluded vessel to the thrombus to be treated.  This study 
complements previous computer simulations that analyzed the kinetics and diffusive 
transport of thrombolytics through a clot but did not consider the transport through the 
occluded vessel [Anand and Diamond (1996), Diamond and Anand (1993)].  Since the 
diffusion-limited transport through the occluded vessel is rate limiting, this study is vital 
to more accurately determine the time needed to deliver the required amount of 
streptokinase or tPA.  Different occluded vessel geometries and flow rates are considered. 
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2.2 MODEL DESCRIPTION 
To understand the time required for streptokinase and tPA to be delivered to a 
thrombus, simulations were developed to describe the convective and diffusive transport 
and reactions of the drugs in an artery.  The geometry of the model (Figure 2.1) 
incorporates the thrombus, a segment of the unblocked vessel from which the occluded 
vessel branches, and the length L of the clogged vessel between the clot and the branch 
point. For these simulations, the typical radius of the nearby unblocked vessel is assumed 
to be 0.5 mm.  Other geometric variables include the angle θ between the blocked and 
unblocked vessels, the diameter D of the occluded vessel and the length L to the 
occlusion.  The blood flow rate is Q. The angle is measured on the downstream side of 
the occluded vessel and simulations were run for θ = 30°, 45°, and 60°. The diameters D 
of simulated clogged vessels were assumed to range from 0.5mm to 0.75mm to 1mm.  
The length of the blocked vessel, as well as position along the vessel, is measured along 
its upstream side from the unblocked vessel to the thrombus.  Simulations were 
performed for lengths of 0.25cm, 0.5cm, and 0.75cm.   
 
Figure 2.1: Geometry of model simulating thrombolytic drug delivery. The geometric 
system variables of occluded vessel length L, occluded vessel diameter D, 
and angle between the clogged and unblocked vessels θ are shown. 
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Using a more complex geometry does not change the qualitative nature of our 
conclusions.  As will be seen, the flow only penetrates approximately two diameters into 
the occluded vessel.  After that point, transport is completely diffusive.  A more tortuous 
diffusion path of a curved cerebral artery only increases the diffusive length, which is 
essentially the contour length of the occluded artery in this study.  The bulk flow rates in 
the unobstructed artery were set to 1mL/min, 2mL/min, and 3mL/min.  In a 1mm 
diameter artery these flow rates are equivalent to superficial velocities of 2.12cm/s, 
4.24cm/s, and 6.36cm/s, respectively.   
The blood flow’s conservation of mass is described by the continuity equation, 
given by 
 0∇⋅ =u ,  (2.1) 
where u is the velocity vector.  Assuming blood is a completely incompressible fluid, the 
Navier-Stokes equation governing the blood flow becomes 
 ( ) ( )( )Tptρ ρ µ
∂  + ⋅∇ = ∇⋅ − + ∇ + ∇ +
 ∂
u u u I u u F ,  (2.2) 
where p is pressure, and F denotes external forces. The physical properties of blood are 
assumed to be similar to water, so its density ρ is set to 1,000kg/m3 and its viscosity μ is 
set to 10-3Pa∙s.  Since the introduction of the thrombolytic into the bloodstream should 
alter the blood flow itself very little, the blood flow is assumed to be at steady state on 
average so that the derivative with respect to time t drops out of the equation.  For this 
study, the flow is assumed constant and so only the pressure gradient is determined in the 
Navier-Stokes equations.  For this assumption, the relative pressures between different 
points in the flow domain are all that matter, while the absolute pressure is not relevant to 
the fluid dynamics. 
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The boundary conditions are no slip ( 0=u ) at the vessel walls and at the clot.  At 
the upstream end of the unblocked vessel, the velocity is set equal to the superficial 
velocity.  The viscous stress is assumed to be zero at the outlet. 
The convective-diffusive-reactive transport of the thrombolytic drug τ and 
plasminogen P is described by  
 ( )D R
t τ
τ τ τ∂ + ⋅∇ +∇⋅ − ∇ =
∂
u ,  (2.3) 
 ( )P
P P D P R
t
∂
+ ⋅∇ +∇⋅ − ∇ =
∂
u ,  (2.4) 
where R represents the rate of reaction and Dτ and DP represent the diffusion coefficients 
of the thrombolytic and plasminogen, respectively.  The diffusion coefficients for 
streptokinase, tPA and plasminogen are assumed to be approximately the same.  A 
typical diffusion coefficient for a small protein in water is between 10-9m2/s and 10-10m2/s 
[Norris et al. (2012), Reilly (2008)], so Dτ = DP = 3mm2/hr or 8.3×10-10m2/s.  For 
streptokinase R = –k[S][P] without any particular fibrin specificity [Runge et al. (1989)].  
Plasminogen is produced by the liver and introduced into the systemic circulation 
resulting in a standard concentration of 122mg/L (1.506μM) in flowing blood plasma 
[Barlow et al. (1969), Leipnitz et al. (1988)].  In the bulk bloodstream, a pseudo-reaction 
rate constant (k’=k[P]) was calculated using streptokinase’s half-life of 23 minutes 





−= .  (2.5) 
The pseudo-reaction rate constant is therefore 5.023×10-4 s-1 and then the reaction rate 
constant k = 0.3335m3mol-1s-1. 
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 tPA and plasminogen react according to Michaelis-Menten enzyme-substrate 
kinetics, and the reaction rate for tPA is R =-0.07s-1[T][P]/(83μM+[P]) [Runge et al. 
(1989)].  For these convection-diffusion-reaction equations, the boundary conditions are 
zero flux through the vessel walls, no flux of free plasminogen through the clot, and 
negligible concentration change with position at the outlet.  At the inlet, the concentration 
of plasminogen is set to 1.506×10-3mol/m3 or 1.506μM. 
 The time variation of the concentration of the thrombolytics at the inlet is more 
complex.  When streptokinase is used to treat a stroke, up to 1.5 million units are 
administered by IV into the neck or arms over the course of one hour [Verstraete (1987)].  
Here, a lower dose of one million units in an hour is used to decrease the probability of 
bleeding complications.  Since purified streptokinase has an activity of approximately 
70,000 units/mg, a million units amount to 0.0143g [Banerjee et al. (2004)].  A typical 
patient would have a blood volume of about 5.2L and a cardiac output of approximately 
5L/min [Herman (2007)].  Nearly all his blood would complete at least one cycle, 
traveling from the heart to the organs or extremities and back again, in about one minute.  
Dilution of the thrombolytic in 5.2L of blood over the course of one hour yields 
1.614×10-8mol∙m-3s-1 since streptokinase has a molecular weight of 47,287g/mol [Parrado 
et al. (1996)].  It should take roughly half a minute for blood to travel from the 
administration point for the thrombolytic to the thrombus.  Solving equation (2.5) for the 
streptokinase concentration per unit time after 30 seconds yields 1.590×10-8mol∙m-3s-1 as 
the concentration at the inlet to the simulated region at the start time for the simulation 
(t=0s), 30 seconds after the drug’s administration.  Between t=0s and t=3600s, the 
concentration would increase by 1.590×10-8mol/m3 every second as thrombolytic 
continues to be administered except the thrombolytic is continually reacting in the 
bloodstream according to equation (2.5).  As such the inlet concentration of streptokinase 
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during the first hour Si1 must account for both the IV administration and half-life of 
streptokinase. 
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The systemic plasminogen concentration outside the simulated region is assumed to be 
constant since it can be replenished by the liver.  Note at t=3600s, the inlet concentration 
peaks at 2.647×10-5mol/m3.  After the first hour, it is assumed that the inlet concentration 
of streptokinase decays exponentially from its peak value according to its half-life:  
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 The inlet concentration of tPA is obtained in a similar manner. tPA is also 
delivered by IV into the neck or arms over the course of an hour, but the amount depends 
upon the body mass of the patient.  0.9mg of tPA are administered per kilogram of body 
mass [Eissa et al. (2012)], so for an ordinary 75kg person a total of .0675g of tissue 
plasminogen activator would be used [McDowell et al. (2008), Walpole et al. (2012)].  
tPA has a molecular weight of around 70000g/mol [Van de Werf (1999)], so diluting it in 
5.2L of blood over the course of an hour gives 5.151×10-8mol∙m-3s-1.  After 30 seconds, 
the initial inlet concentration for tPA is 4.962×10-8mol∙m-3s-1.  Setting the free 
plasminogen concentration to 1.506μM, the reaction rate for tissue plasminogen activator 
becomes -1.2475×10-3s-1[T], and from that the inlet concentration of tPA Ti is defined. 
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Again, note at t=3600s, the inlet concentration peaks at 3.934×10-5mol/m3.  After the first 
hour, the inlet concentration of tPA decays exponentially from its peak value:  
 ( )( )
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 Another boundary condition is the reaction rate of the thrombolytic and 
plasminogen at the clot.  Forming and developed thrombi have an elevated plasminogen 
concentration compared to flowing blood plasma.  A typical plasminogen concentration 
within a thrombus is 2.116μM [Cederholm-Williams (1981)].  To simplify the analysis, 
the bound plasminogen concentration [Pb] within the clot is assumed constant.  While 
streptokinase is believed to penetrate into the clot and perform endogenous fibrinolysis, 
the boundary condition for the thrombus would be best implemented as a flux or surface 
reaction rate.  In order to convert the bulk reaction rate to a surface reaction rate, a 
characteristic clot thickness δ is defined as D kτ .  Multiplying the characteristic clot 
thickness with the bulk reaction rate approximates the flux through the surface of the 
thrombus.  For streptokinase, the clot thickness is 1.084×10-3m (1.084mm), and the 
reaction’s mechanism and rate constant remain the same as in the bulk flow.  As a result, 
the flux is 7.653×10-7m/s times the local concentration of the streptokinase.  For tPA, the 
fibrin in the thrombus catalyzes the reaction, changing the Michaelis-Menten type 
reaction rate to 0.28s-1[T][Pb]/(0.18μM+[Pb]), or 0.258s-1[T] [Runge et al. (1989)].  The 
characteristic clot thickness is 5.671×10-5m and the flux is 1.4635×10-5m/s times the local 
concentration of tPA at the surface of the thrombus. 
 The equations were solved numerically using the finite-element package 
COMSOL.  In order to reduce the required computational time and memory, the 
simulated system geometry is symmetrically split in half.  The centerlines of the two 
arteries define the plane symmetrically splitting the system.  This split results in an 
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additional boundary, but symmetry defines the necessary conditions.  In the Navier-
Stokes equation, the net flow across the symmetry boundary is zero, and in the 
convection-diffusion equation, the net flux of the protein across the boundary is zero.  
With the system geometry and its domain and boundary conditions defined, the only 
remaining issues are the initial conditions for the transient convection-diffusion problem 
of the thrombolytics and plasminogen.  At t=0s, no thrombolytic has entered the 
simulated region yet so its concentration throughout is 0mol/m3.  Also, at the start of the 
simulation, no thrombolytic has yet reacted with the plasminogen in the occluded vessel 
and the systemic plasminogen concentration outside the simulated region is assumed to 
be constant at 1.506μM. 
 Using these equations and conditions, the base case of L=0.5cm, D=0.5mm, 
θ=45°, and Q=2mL/min was solved, first for streptokinase and then for tPA, to obtain the 
local concentration of the thrombolytic at the clot site.  This was achieved by 
simultaneously solving the Navier-Stokes and continuity equations under steady state 
conditions and then using the velocity field profile obtained to solve the transient 
convection-diffusion equation with 10 second time steps.  Subsequently, another 16 cases 
were simulated (8 for streptokinase and 8 for tPA) in which each system variable was 
changed individually while the other variables remained at their base values. 
2.3 CONCENTRATION PROFILES 
Concentration profiles of the simulated region were obtained for the base case one 
hour after the first thrombolytic molecules reached the inlet.  After one hour, the 
concentration of streptokinase ranges from 0.48nM at the clot to 26.5nM in the 
unblocked vessel (Figure 2.2a). When streptokinase is used, the concentration profile of 
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plasminogen has a peak value of 1.506μM in the unblocked vessel and a minimum value 
of 1.502μM near the middle of the occluded vessel (Figure 2.2b). 
 
 
Figure 2.2: Typical concentration profiles one hour after start of streptokinase 
administration with system variables set to L=0.5cm, D=0.5mm, θ=45°, and 
Q=2mL/min. a) Concentration profile for streptokinase, b) concentration 
profile for plasminogen.  Note that convection transports the streptokinase 
partially up the branched vessel, but diffusion is required to deliver it to the 
thrombus. 
For the base case, about an hour after the start of administration, the concentration 






Figure 2.3: Typical concentration profiles one hour after start of tissue plasminogen 
activator (tPA) administration with system variables set to L=0.5cm, 
D=0.5mm, θ=45°, and Q=2mL/min. a) concentration profile for tPA, b) 
concentration profile for plasminogen.  Note that convection transports the 
tPA partially up the branched vessel, but diffusion is required to deliver it to 
the thrombus. 
Still analyzing the thrombolytic concentration profile one hour after the beginning 
of IV administration, the effect of changing each of the system variables is investigated.  
For streptokinase, decreasing the branch angle from 45° to 30° causes the local 
concentration at the clot to increase from 0.48nM to 0.71nM (Figure 2.4b).  
Increasing the occluded vessel diameter from 0.5mm to 1mm causes the local 
concentration of streptokinase at the thrombus after one hour to increase from 0.48nM to 
1.54nM (Figure 2.4c).  Decreasing the volumetric flow rate through the unblocked vessel 
by a factor of two from 2mL/min to 1mL/min only shifts the streptokinase concentration 
at the thrombus from 0.48nM to 0.45nM for a change of about 6 percent (Figure 2.4d).  
Decreasing the length of the occluded vessel by a factor of two from 0.5cm to 0.25cm, 
however, allows the thrombolytic concentration to rise from 0.48nM to 6.36nM at the 





Figure 2.4: Concentration profiles demonstrating effect of changing system variables. a) 
Base case of L=0.5cm, D=0.5mm,  θ=45°, and Q=2mL/min using 
streptokinase, b) angle changed to 30°, c) diameter of clogged vessel 
changed to 1mm, d) flowrate changed to 1mL/min, e) length of blocked 
vessel changed to 0.25cm. 
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2.4 TRANSIENT THROMBOLYTIC DELIVERY 
In order to determine the total amount of thrombolytic that is ultimately delivered 
to a clot as a result of one hour IV administration to the neck or arms, the transient 
concentration of the drug at the thrombus must be considered.  A complete analysis also 
requires at least three sets of data for each variable system parameter to establish a 
pattern.  Tracking the clot concentration of both streptokinase and tPA over time at 
different values of θ further confirms the pattern suggested by the values found for 
streptokinase at 30° and 45° after one hour.  The concentration also decreases when the 
angle is changed from 45° to 60° (Figure 2.5a-b).  While the maximum inlet 
concentration is obtained one hour after the first thrombolytic molecules reached the 
inlet, the peak thrombus concentration is obtained about 1.5 hours after t=0s, slightly 
earlier for tPA.  The tPA concentration at the thrombus decreases to a negligible amount 
relative to its maximum after 2.5-3 hours, while 4.5-5 hours are needed for the local clot 
concentration of streptokinase to become negligible.  The tPA concentration peaks 
slightly earlier, decays faster after peaking, and experiences a noticeable decrease in its 
first derivative around one hour, when the thrombolytic stops being administered, all 
because tPA is consumed faster in the bulk bloodstream than streptokinase.  The even 
more rapid reaction of tPA at the thrombus makes it very difficult for a high 
concentration to be obtained there.  The concentration at the thrombus is not a 




Figure 2.5: Transient plots showing the effect of changing the branch angle from 30° to 
45° or 60° in the simulation and the time required for the thrombolytics to 
react at the thrombus. a) Concentration of streptokinase at the thrombus over 
time, b) concentration of tPA at the thrombus over time, c) cumulative 
amount of streptokinase that has reacted at the clot over time, d) cumulative 
amount of tPA that has reacted at the clot over time. 
The cumulative amount of thrombolytic that has been delivered to the clot at any 
given time is a parameter of interest since it is proportional to the number of plasmin-
fibrin reactions that have occurred at the clot under the assumption that any plasminogen 
activated in the bulk bloodstream is inhibited by α2-antiplasmin before reaching the 
thrombus.  Assuming the fibrin-bound plasminogen concentration in the thrombus is 
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constant, the local thrombolytic concentration is directly proportional to the flux and the 
number of moles of thrombolytic reacting at the clot at any given second.  Integration of 
the latter value over time gives the cumulative number of moles of delivered 
thrombolytic. In plots of the cumulative amount of thrombolytic delivered, the time at 
which the maximum local clot concentration was obtained can be identified by the 
inflection point of the curve.  The subsequent rapid decay in the concentration of tPA 
appears as a rapid transition to the final total amount of tPA delivered. 
As θ increases from 30° to 45° to 60° the total amount of streptokinase delivered 
to the clot decreases (Figure 2.5c) as does the total amount of delivered tPA (Figure 
2.5d).  As the occluded vessel diameter is increased from 0.5mm to 0.75mm to 1mm, the 
total amount of streptokinase or tPA delivered increases following a power law 
relationship (Figure 2.6a-b). As the flow rate through the unblocked vessel is varied from 
1mL/min to 2mL/min to 3mL/min, the total amount of thrombolytic delivered barely 
changes (Figure 2.6c-d). As the length of the occluded vessel increases from 0.25cm to 
0.5cm to 0.75cm, the amount of delivered thrombolytic decays exponentially with 






Figure 2.6: Transient plots comparing the effect of the diameter (a,b), the flow rate 
(c,d), and the length (e,f) on the cumulative amount of thrombolytic 
delivered to the thrombus over time when using SK (a,c,e) or tPA (b,d,f). 
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2.5 DISCUSSION AND CONCLUSIONS 
The results show that the process of thrombolytic delivery to a clot in a 
completely blocked vessel is diffusion limited.  After the thrombolytic enters the 
occluded vessel, it diffuses through the artery until it reacts with plasminogen.  Since 
diffusion is a slow transport mechanism and the thrombolytic and plasminogen are 
continually reacting with each other, their concentrations decrease with distance along the 
occluded vessel.  Thus, the minimum thrombolytic concentration occurs at the clot.   
After one hour from the start of administration, the minimum concentration of 
tPA (0.03nM), which occurs at the thrombus, is even lower than that of streptokinase 
(0.48nM) because tPA reacts more rapidly than streptokinase both at the clot surface and 
in the bulk flow.  A total of 0.0738fmol of streptokinase and 0.126fmol of tPA are 
delivered to the thrombus during the administration period.  This accounts for only 11.3% 
of the total streptokinase that eventually reacts at the clot but 35.2% of the total tPA. The 
increase in local concentration at the clot with decreasing branch angle can be attributed 
to a slight increase in the distance over which convection transports the drug into the 
occluded vessel.  In the case of decreasing the branch angle, this convective penetration 
of the blocked artery is improved because the blood and the thrombolytic it carries can 
deviate from the bulk flow in the unblocked artery by a smaller angle and therefore 
oppose the flow’s inertia less.  In addition, the convective penetration distance increases 
because the entrance to the clogged vessel (D/sinθ) becomes wider.  In fact, the 
convective penetration distance is roughly 2 sinD θ .  The resulting trend of increased 
thrombolytic delivery with decreased branch angle also suggests that the total 
thrombolytic delivered is proportional to 1/sinθ, which is proportional to the width of the 
entrance to the occluded vessel.  The proportionality constant relating 1/sinθ to the total 
thrombolytic delivered is approximately 0.34 for streptokinase and 0.31 for tPA.   
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The link between increasing occluded vessel diameter and increasing local 
thrombolytic concentration at the clot is again the increase in the width of the blocked 
artery’s entrance leading to drastically improved convective penetration.  Improved 
thrombolytic delivery naturally follows the increased thrombolytic concentration at the 
clot.  The number of micromoles of streptokinase delivered is 20.275D3.181, and the 
number of micromoles of tPA delivered is 1655.3D3.841, where D has units of meters.  
Tripling the flow rate accounts for less than a six percent change in the total streptokinase 
delivered and less than a ten percent change in tPA delivered.  This shows that the flow 
rate has a weak effect on the local clot concentration of the thrombolytic.  When doubling 
the flow rate, the streptokinase delivered increases by four percent and the tPA delivered 
increases by 6.6 percent.  Length is by far the most significant variable with the amount 
of delivered thrombolytic decaying exponentially with increasing length.  The 
concentration profile of the drug remains nearly identical when the length of the occluded 
vessel is altered, so the length of the artery does little to affect the flow through it.  The 
number of femtomoles of streptokinase delivered to the clot is 32.02e-778L, and the 
number of femtomoles of tPA delivered to the thrombus is 165.5e-1227L, where L has units 
of meters.   
tPA and streptokinase behave quantitatively different since tPA has a greater 
fibrin specificity and a greater reaction rate both at the thrombus and in the bulk flow.  
Typically for the simulated cases, more thrombolytic is delivered to the clot if 
streptokinase is administered than if tPA were administered in large part because 
streptokinase reacts more slowly in the bulk bloodstream.   However, this is not the case 
when the length of the occluded vessel is shortened to 0.25cm from the base case of 
0.5cm.  When the occluded vessel’s length is 0.366cm and other variables are at their 
base values, the total amount of delivered thrombolytic should be 1.85fmol no matter 
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which drug is used.  For vessel lengths shorter than about 0.366cm, more thrombolytic is 
delivered to the clot if tPA is used instead of streptokinase.  This effect results from the 
delivered tPA being much more sensitive to L than delivered SK.  In fact tPA is much 
more sensitive to all the system variables compared to streptokinase. 
The diffusion-limited rate of transport and delivery in the occluded vessel, 
convective transport past the occluded vessel, and systemic reactions with plasminogen 
combined make it likely that only a small portion of the administered thrombolytic will 
actually react at the clot.  In fact the results here suggest that often an insufficient amount 
of the drug is reaching the thrombus.  Of the 0.30μmol of streptokinase administered by 
IV only about 0.65fmol (2.16×10-7 percent) are delivered to the thrombus under the base 
conditions with an occluded vessel length of 0.5cm.  Of the 0.96μmol of tPA 
administered only 0.36fmol (3.7×10-8 percent) react at the clot for the same length.  A 
shorter occluded vessel, 0.25cm long, yields better, but still undesirable, results:  
1.52×10-6 percent for streptokinase and 8.02×10-7 percent.  Interestingly, despite the 
much improved fibrin specificity of tPA, a greater fraction of the administered 
thrombolytic is delivered if streptokinase is used in lieu of tPA.  Vastly improved fibrin 
specificity is unimportant if the reaction rate of the thrombolytic in the bulk blood plasma 
is already fast since the drug may never reach the clot site. 
This diffusion-limited transport may be a primary reason that, even now, 
individuals suffering a stroke have about an 80 percent chance of death or disability 
[Kwon et al. (2004), Roger et al. (2012)].  The large scale trials by the European and 
European-Australasian Cooperative Acute Stroke Studies (ECASS I and II) and 
ATLANTIS (Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic 
Stroke) of intravenously delivered alteplase, a recombinant tPA, found that its use for 
acute ischemic stroke treatment could not be definitively shown to be an improvement 
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over the use of a placebo [Donnan et al. (2003)].  The Third International Stroke Trial 
(IST-3), the largest scale-trial yet, was able to prove a very tiny improvement in the 
overall likelihood of surviving the stroke without disability if thrombolytic is 
administered within three hours of the stroke’s onset.  However, between three and six 
hours after the stroke, the majority of their data suggests that tPA actually diminishes 
those odds as well as the probability of surviving at all versus placebo [Wardlaw et al. 
(2012)].  In patients who are healthy enough, intra-arterial delivery directly into the 
occluded vessel, or even better at the clot site, would be extremely beneficial since it 
would avoid convective transport past the occluded vessel, systemic dilution and reaction 
of the thrombolytic, and decrease the diffusive length.  Otherwise the effective use of 
thrombolytics remains elusive unless the mechanism of delivery is radically altered. 
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Chapter 3: General Model for Magnetically-Assisted Thrombolytic 
Delivery 
3.1 INTRODUCTION 
Inducing convective transport in dead-end pores is valuable for improving many 
processes.  When reservoirs are waterflooded and subsequently re-flooded with alkali-
surfactant-polymer solutions to displace and recover oil, a substantial amount of oil may 
be left behind, trapped within dead-end pores [Farajzadeh et al. (2013), Sedaghat et al. 
(2013)].  Convection of the flooding solution can lead to improved delivery of surfactants 
and alkalis to decrease interfacial tension or lead directly to convection of the oil.  Both 
mechanisms would aid in removing the oil from the blocked pore.  Similarly, pores can 
also trap environmental contaminants, like dense non-aqueous phase liquids, 
complicating subsurface remediation [Miller et al. (2000)].  Convection of the flushing 
medium can assist in the rapid cleanup of these contaminants.  In ischemic stroke 
patients, delivering clot-busting thrombolytics to the site of the blood clot is time 
sensitive and slow diffusion-limited delivery of the drug through the length of the 
blocked artery is an issue [Clements and Bonnecaze (2013), Donnan et al. (2003)].  
Inducing convection within the blocked artery can speed delivery of the thrombolytic to 
the clot. 
There are many different methods of inducing fluid flow in general, ranging from 
the classical, such as pressure and gravity, to thermally induced buoyancy changes, which 
is popular for processes involving gases on a large scale, like building ventilation [Gan 
(2006)].  The more difficult issue is finding methods of generating fluid flow that can be 
applied to a range of systems that do not have separate inlets and outlets, in addition to 
being small-scale and typically difficult to access directly, for example being 
underground or inside the human body.  Electro-osmosis is currently popular for use in 
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oil recovery since ions are plentiful in crude oils permitting a strong driving force [Chen 
S. et al. (2014)].  The use of acoustic vibrations is currently seeing increased interest as it 
may, in addition to inducing fluid flow [Sun and Guo (2007)], also bypass the issue by 
destroying the blockage, as in sonothrombolysis [Chen X. et al. (2014)]. 
Magnetically-driven flow in blocked pores via a method invented by Pulse 
Therapeutics is explored here.  Ferroparticles are added to the fluid medium.  A magnetic 
field is applied to the region of interest and in response the ferroparticles aggregate.  In 
order to subsequently induce flow, the field is rotated, creating torque on the aggregates 
leading to their rotation within the bulk fluid.  The rotating magnetic field must also have 
some gradient in order to establish a concentration gradient for the ferroparticle 
aggregates so that directional flow is possible within a blocked vessel. 
Demetriades (1958) explored the effect of applying an electric field to rigid 
particles already immersed in a shear flow.  The orientation of the particles was solved 
for with the electric field set normal to the shear flow.  Mason co-wrote a series of 
articles on particle behavior when placed under the influence of both a shear field and an 
electric field, including one with Allan (1962) in which the orientation of a rigid rod is 
briefly presented for the case of zero shear flow.  Shine and Armstrong (1987) considered 
the transient rotation of an axisymmetric ellipsoid in response to a constant, uniform DC 
magnetic field without the initial shear flow.  In addition to the magnetic and 
hydrodynamic torques contributing to the net torque on the ellipsoid, they also focused on 
the relationship between the applied magnetic field and the magnetization of the 
ellipsoid.  This included finding a perturbation solution for ellipsoids near their saturation 
magnetization due to a high strength magnetic field.  Horvath and Kopcansky (1993) 
developed a qualitative model for the rotation of a magnetic dimer in the presence of a 
rotating magnetic field and performed stability analyses on it.  They noted the existence 
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of a critical parameter above which the dimer would rotate in sync with the field, while 
below it rotation would be asynchronous.  Their analysis, however, does not extend to 
investigating the influence of the rotating dimer on the surrounding fluid medium. 
The magnetic body couple and magnetic body force acting on the ferro-
aggregates must be noted when considering the stresses on the fluid continuum.  The 
body couple is the divergence of the anti-symmetric stress, which is defined by the 
torques acting on the aggregates.  At steady state, the magnetic torque, controlled by the 
cross-product of the magnetization of the aggregates and the applied magnetic field, is 
balanced by the hydrodynamic torque.  The body force is the dot product of the 
magnetization of the aggregates and the gradient of the magnetic field.  The H-field 
gradient is here considered to be only of sufficient strength to establish the concentration 
gradient, while contributing minimally to the body force.  
3.2 MODEL DESCRIPTION 
In order to predict the fluid velocity profile of a dilute suspension of ferroparticles 
in a blocked channel when subjected to a rotating magnetic field and to better understand 
the physics leading to convective flow, a model was developed to describe both the 
particle dynamics and the flow field.  The geometry of the system was set up as shown in 
Figure 3.1, where M  is the magnetic dipole moment of the magnetic field source. 
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Figure 3.1: Schematic of model system showing particle aggregates, potential flow 
field, and rotating magnetic field source. 
In order to reduce the complexity of the system, the model assumes that the 
spherical ferroparticles have already aggregated into slender structures in response to the 
presence of the magnetic field and that those aggregates have already positioned 
themselves within the channel according to the strength of the field’s gradient.  Each 
slender aggregate will be treated as a single, larger, ellipsoidal particle. 
The model equations describing the suspension dynamics include conservation of 
mass (3.1) and linear momentum (3.2), given by 
 0∇⋅ =u ,  (3.1) 
 2 0A
D p n V
Dt
ρ η µ= −∇ + ∇ +∇⋅ + ⋅∇u u T m h ,  (3.2) 
where u is the velocity vector, ρ is the fluid density, t is time, p is pressure, and η is fluid 
viscosity. 0n Vµ ⋅∇m h is the magnetic body force, where n is the local ferro-aggregate 
number density, 0µ is the magnetic permeability in a vacuum, V is the aggregate volume, 
m is the magnetization of the aggregates, and h is the applied magnetic field.  TA is the 
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anti-symmetric stress tensor resulting from the body couple of the applied magnetic field 















 = − 
 − 
T . (3.3) 
The ferro-aggregate number density is described by the equation: 
 ( )n n n
t
∂
+ ⋅∇ = ∇⋅ ⋅∇
∂ g
u d ,  (3.4) 
where ug is the particle velocity across the channel due to the magnetic field gradient and 
d is the effective hydrodynamic diffusion tensor of the aggregates. 
The magnetic torque TM on the aggregates must be found to specify TA, thereby 
linking the suspension dynamics with the particle dynamics.  The magnetic component of 
the torque on the aggregates is given by 
 ( )0M Vµ= ×T m h . (3.5) 
The magnetization of the aggregates is described by 
 L Tα α= ⋅ +m pp h h ,  (3.6) 
where p is the director describing the orientation of the aggregates, 
( )( ) ( ) 122 3 ln 2 / 1L L a L aα
−
 = −   and 2Tα =  [Rocha and Acrivos (1974)].  L is the 
length of the semi-major axis and a is the length of the semi-minor axis. 
The hydrodynamic torque on the aggregates is given by [Kim and Karrila (1991)]  
 ( ) ( ) ( )( )38 -C C HH L X Y Yπη ∞ ∞  = + − + × ⋅   T pp I pp ω ω p e p ,  (3.7) 
where ω is the angular velocity of the aggregates, ω∞ is the angular velocity of the bulk 
fluid, and e∞ is the strain rate due to the flow.  The parameters XC, YC, and YH are known 
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functions of aggregate eccentricity, 2 2L a Lε = − , and are listed in Appendix B [Kim 
and Karrila (1991)]. 
Following Jeffery (1922) and Hinch and Leal (1979), the angular velocity of the 




p K p ω .  (3.8) 
See Appendix B for K(p). 
Setting the magnetic and hydrodynamic torques equal to one another results in a 

















  ⋅ + ×  
 = ⋅ + +   
   − × ⋅    
pp h h hp K ω pp I pp
p e p
  (3.9) 
3.3 NON-DIMENSIONALIZATION 
The first step in analyzing these equations is to appropriately non-dimensionalize 
them.  To that end, dimensionless time and distance have been defined as tτ = Ω and 
X x d= , respectively, where Ω is the rotation rate of the magnetic field and d is the 
channel diameter.  Similarly, aggregate rotation rate is non-dimensionalized according to 
= ΩΩ ω .  The dimensionless magnetic field and magnetization are H=H h and 
LHα=M m , respectively, where H is the magnetic field strength.  Dimensionless 
concentration is represented by N nV= Φ , where Φ is the average volume fraction of 
the aggregates, and dimensionless torque is represented by 3M MG T Lη= Ω . 
Based upon the following analysis, a characteristic velocity of 3cu L d V= Ω Φ
was chosen, making the dimensionless velocity 3V L d= Φ ΩU u .  Accordingly, the 
characteristic pressure is defined as c cp u dη= , while the characteristic diffusion 
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coefficient is defined as c cD u d= .  Finally, the characteristic values of the local flow 
rotation rate and strain rate are c c ce u dω
∞ ∞= = . 
Following these definitions, non-dimensionalizing equations (3.1-3.5) gives 
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 − 
G ,  (3.12) 
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L τ
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= ×  Ω 
G M H .  (3.14) 
Since the magnitude of sinMH θ× =m h , where θ is the offset angle between the 
H-field and magnetization vectors, the magnitude of sinθ× ≈M H . 





= ⋅ +M pp H H ,  (3.15) 
 ( ) ( )
3 3
8 -C C HH
L LX Y Y
V V
π ∞ ∞
  Φ Φ   = + − + × ⋅       
G pp I pp Ω Ω p E p .  (3.16) 
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  (3.17) 
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∝ .   (3.19) 
3.4 DISCUSSION AND CONCLUSIONS 
Based upon these non-dimensionalizations, several conclusions can be drawn 
about the behavior of the magnetically-induced velocity.  The velocity scales 
proportionally to both the volume fraction of the aggregates and the rotation rate of the 
magnetic field.  Similarly, since the characteristic velocity is also proportional to 3L V , 
assuming ellipsoidal aggregates, the magnetically-induced velocity scales proportionally 
with 2 2L a , or the square of the aspect ratio of the aggregates. 
Interestingly, velocity is seen to be independent of the magnetic field strength.  
This independence is only possible due to the assumption that the aggregates are of fixed 
length and aspect ratio.  When this assumption is eliminated in Chapter 6, the velocity 
will be shown to be influenced by the H-field strength.  With the aggregates of fixed size 
as in Chapters 4 and 5, however, torque is independent of the magnitude of the magnetic 
field.  This occurs because the torque is explicitly dependent upon the product of the 
magnetic field strength, the magnetization of the aggregates, and the sine of the offset 
angle between the two.  Since the magnetization of the aggregates is proportional to H 
and the sine of the offset angle is inversely proportional to H2, the magnetic field strength 
dependence of the torque is canceled out. 
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Since H is the magnetic field strength applied to the region of interest and not the 
magnetic field strength at the source, changing the location of the magnetic field source 
as done in Chapter 5 will not impact the preceding non-dimensionalizations and their 
corresponding scaling arguments. 
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Chapter 4: 2D Model with Fixed Size Aggregates in a Non-Displaced 
Magnetic Field 
4.1 EQUATIONS 
Following the equations from Chapter 3, consider a flow that has been 
magnetically induced from quiescence in a two-dimensional channel where inertia, 
magnetic body force, strain rate, and the angular velocity of the bulk fluid are negligible.  
Also, within the region of interest, the magnetic field is assumed to be spatially constant, 
varying only with time, while the local aggregate number density varies only with x-
position across the channel.  In addition, the magnetic field source is assumed to be 
located at the channel in the region of interest.  As noted previously, the slender 
aggregates will be treated like larger individual ellipsoidal particles of constant, fixed 
aspect ratio and length.  
 
Figure 4.1: Schematic of model system showing particle aggregates, potential flow 
field, and rotating magnetic field source. 
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, (4.3) 
The dynamics of a rod in the flow are given by 
 ( ) ( )2 2sin cos sin cos sin cos sinsin
x
x y y x y x
dp H H H H H H
d
φ φ φ φ φ φ φ
τ θ
 = − + − +  ,  (4.4) 
 ( ) ( )2 2cos cos sin cos sin cos sinsin
y
x y y x y x
dp
H H H H H H
d
φ φ φ φ φ φ φ
τ θ
 = + − +  ,  (4.5) 
where ( )1tan y xp pφ −= is the orientation angle of the ferro-aggregate.  As such, 
sinyp φ=  and cosxp φ= . 
The x and y components of the dimensionless magnetic field are assumed to be 
given by ( )cosxH τ=  and ( )sinyH τ= .  It is further assumed that the fluid flow velocity 
across the channel is negligible and that the bulk flow velocity uy does not change with y-
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= − .  (4.9) 
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The offset angle between the H-field orientation and the orientation of the 
aggregates is θ τ φ= − . For sufficiently strong magnetic fields, the offset angle will be 
constant, so aggregate rotation rate ( )d dtφ  will match the H-field rotation rate (Ω).  
Therefore, 1d dφ τ = , and since ( )( )dp d dp d d dτ φ φ τ= , it follows that 
dp d dp dτ φ= .  sinxdp dφ φ= −  and cosydp dφ φ= , so ( )sin 2 2 2sin 1τ φ θ− = , or 
( )sin 2 2sinθ θ= .  In the case of a small offset angle, as would exist in the presence of a 
strong magnetic field, this equation is valid as the approximation sinθ θ=  holds so 
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U Y N C X Cπ ψ∂= −
∂
+ +∫ ,  (4.15) 
where ψ is simply being used as a variable of integration in place of X. 
Applying the no-slip ( 0yU = ) boundary condition at 0X =  gives 
 2 0C = .  (4.16) 
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Applying the no-slip boundary condition at 1X =  and noting that 
1
0








= − .  (4.17) 
Substituting the values of C1 and C2 into equation (4.15) yields 
 












∂ ∫ .  (4.18) 
In an unblocked channel, the pressure gradient vanishes giving an expression for 
the magnetically-driven flow velocity: 
 ( )08 dXCmU Y X Nπ ψ= − ∫ .  (4.19) 
In a blocked channel, the spatially-averaged net velocity must be zero with the 
average magnetically-driven and pressure-driven flow rates cancelling one another.  The 
pressure gradient is then given by 
 ( )10 048 1 2 d dXCP Y N XY π ψ
∂  = −  ∂ ∫ ∫ .  (4.20) 
Inserting the solution for the pressure gradient into the expression for the net flow 
velocity gives  
 ( ) ( )12 20 0 08 3 2 d 6 d dX XCyU Y X X N X X X N Xπ ψ = − − − −  ∫ ∫ ∫ .  (4.21) 
In order to evaluate the flow field in equation (4.21), the concentration field 
across the channel must be obtained.  To do so, it is assumed that a balance exists 
between the force pushing the aggregates toward the wall at a velocity of Ug as a result of 
the magnetic field gradient and the hydrodynamic diffusion D, diffusing the aggregates 
away from the wall.  The constant gU Dβ = , a cross-flow Peclet number, is used to 
quantify the relative transport mechanisms which govern the concentration profile of the 
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aggregates.  The concentration profile would also be expected to be exponential with 
respect to channel position and satisfy equation (3.13).   
 ( )3
V N N N
L τ
∂
+ ⋅∇ = ∇⋅ ⋅∇
Φ ∂ g
U D  (3.13) 
The channel walls are impermeable to the ferroparticles, leading to the boundary 
condition of no flux through the channel wall: ( )
1
0g XU N D N X =− ∂ ∂ = .  The constraint 
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.  (4.22) 
Utilizing this expression for the concentration gives improved expressions for the 
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pU Y X Xπ β β
 
= − + − − 
.  (4.24) 
4.2 PARTICLE DYNAMICS 
4.2.1 Torque 
Computational simulation of the preceding equations gives further insight into the 
particle dynamics of the process and its resulting flow field. 
In order to better understand the rotation of the aggregates, the time-averaged 
torque which causes that rotation is plotted against the applied magnetic field strength as 
shown in Figure 4.2.  From that plot, a critical threshold strength becomes apparent.  
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Above it, there is significant torque on the aggregates with dimensional scaling of 3Lη Ω , 
but below it the torque rapidly drops to zero as if no magnetic field was being applied at 
all.  The value of this critical field strength was found from the simulation results to 












= .  (4.25) 
This value agrees with the scaling obtained by substituting the maximum value of 
sin(θ) possible, 1, into equation (3.19) and re-arranging to solve for H. 
The critical magnetic field strength is a function of viscosity, aggregate geometry, 
and field rotation rate.  Of these parameters, only field rotation rate can be directly 
modified.  Re-organizing equation (4.25), a critical magnetic field rotation rate could be 











Ω =  (4.26) 
Since the critical H-field magnitude is proportional to the square root of the field 
rotation rate, the critical H-field rotation rate is proportional to the square of the field 
magnitude.  The existence of such a critical magnetic field frequency has been 
experimentally verified by Helgesen, Pieranski, and Skjeltorp (1990).  They noted that as 
field frequency decreased the rotation of an affected bound pair of magnetic holes 




Figure 4.2: Dimensionless torque on aggregates when subjected to magnetic fields of 
various amplitudes. 
4.2.2 Orientation Angle 
Figure 4.3 tracks the rotation of the aggregates, plotting their orientation angle 
over time, for three different cases: above, at, and below the critical magnetic field 
amplitude.  An initial condition of ϕ = 0 is used. When the applied magnetic field 
strength is greater than the critical H-field strength, the aggregates rotate in sync with the 
field with very little offset.  When the applied field is weaker than the critical field, 
aggregate rotation is insignificant.  Around the threshold magnitude, the aggregates still 
rotate primarily in one direction, but net aggregate rotation is much slower and bears little 
to no resemblance to the field rotation.   
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Figure 4.3: Orientation angle of the aggregates over dimensionless time for 5Hz 
magnetic fields above, at, and below the critical field strength.  Inset 
schematic of orientation angle in the x-y plane and relative to an aggregate 
director. 
4.2.3 Offset Angle 
Alternatively, this information can be demonstrated by plotting the time-averaged 
offset angle between the orientation of the aggregates and the H-field orientation against 
the magnetic field strength as shown in Figure 4.4.  Above and near the critical field 












= .  (4.27) 
Small average offset angles, which deviate from this equation, are obtained for 
weak magnetic fields below the threshold magnitude because the aggregates have 
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essentially stopped moving and offset angle is bound between –π and π.  As such, the 
times when aggregate offset is negative cancel out those when it is positive. 
 
 
Figure 4.4: Offset angle of the aggregates from the magnetic field when subjected to 
magnetic fields of various amplitudes.  Inset schematic of offset angle in the 
x-y plane and relative to the H-field vector and an aggregate director. 
4.3 FLUID FLOW 
4.3.1 Magnetically-Driven Velocity Profile 
The particle dynamics induce fluid flow within the channel, so the critical field 
strength, which plays such an important role in those dynamics, is also an essential 
parameter of the fluid velocity profile.  Figure 4.5a plots the dimensionless magnetically-
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induced velocity profile across the channel above, at, and below the critical magnetic 
field strength for a 5 Hz applied magnetic field and a particular β of 75, while Figure 4.5b 
does the same for β = 7.5.  Figures 4.5c-d plot the dimensional magnetically-induced 
velocity profile across the channel at different frequencies above the critical threshold for 
β = 75 and β = 7.5. 
 
Figure 4.5: Dimensionless velocity profiles above, at, and below the magnetic field’s 
critical threshold at 5Hz with (a) β = 75 and (b) β = 7.5. Dimensional 
velocity profiles above the critical magnetic field strength by a factor of 10 
at different frequencies for (c) β = 75 and (d) β = 7.5. 
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The greatest velocities are induced above the critical H-field amplitude since the 
aggregates are rotating the fastest, while in the absence of rotation below the threshold no 
flow is induced.  This also explains why increased magnetic field rotation rate leads to 
increased fluid velocity.  Note that Figures 4.5c-d are shown dimensionally because the 
field rotation rate is a parameter of the characteristic velocity. If plotted non-
dimensionally, the different curves would collapse onto the single line shown for H = 
10Hcrit for the corresponding β in Figures 4.5a-b. 
While the amplitude and rotation rate of the magnetic field affect the magnitude 
of the flow field, β influences the shape of the flow field.  β directly controls the shape of 
the concentration profile, relating the magnetic body force and hydrodynamic diffusion 
acting on the particles.  For high β values, the particles are very heavily concentrated 
against one wall of the channel, and this leads to an elevated maximum velocity very 
close to that wall.  As the value of β decreases, the peak concentration decreases.  This 
translates into a decreased peak velocity closer to the middle of the channel. 
4.3.2 Average Velocity and Magnetic Field Rotation Rate 
The dimensional average magnetically-induced velocity is plotted against the 
applied magnetic field frequency above, at, and below the critical H-field strength for β = 
75 and β = 7.5 in Figures 4.6a-b.  As depicted in Figure 4.5, increased magnetic field 
rotation rate yields increased velocity.  Magnetic field amplitudes greater than the 
threshold produce the greatest velocity, while those less than the threshold produce no 




Figure 4.6: Average fluid velocity versus magnetic field rotation rate above, at, and 
below the critical magnetic field strength with (a) β = 75 and (b) β = 7.5. 
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4.3.3 Overall Velocity Profile 
If the channel is blocked, a pressure field will develop in response to drive fluid 
flow away from the blockage. The magnetically-induced, pressure-induced, and overall 
dimensionless velocity profiles, Um, Up, and Uy, respectively are shown for β = 75 and β 
= 7.5 in Figures 4.7a-b. Superposition of the positive magnetically-induced and negative 
pressure-induced flow fields yields the net flow field for the system. The fluid flows 
toward the clot along the far wall and returns from the occlusion by the near wall in 
keeping with continuity, which dictates that the spatially-averaged net velocity along the 
channel must be zero at all times.  As β decreases, the particles become more evenly 
distributed across the channel, and the net velocity profile flattens out as the 
magnetically-induced velocity diminishes and flattens out as well.  As Um becomes 
increasingly spread across the channel, there ceases to be a place for the return flow that 
does not essentially negate the total flow altogether. 
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Figure 4.7: Dimensionless velocity profiles of the magnetically-induced flow Um, the 
pressure-induced flow Up, and the overall, combined flow Uy with the 
applied magnetic field strength ten times greater than the critical threshold 
and (a) β = 75 and (b) β = 7.5. 
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4.4 DISCUSSION AND CONCLUSIONS 
Fluid flow in dead-end pores can be induced by adding ferroparticles to the fluid 
and applying a rotating magnetic field with a gradient.  This fluid flow is induced by the 
rotation of particle aggregates.  Above a critical threshold magnetic field strength, which 
can be estimated as ( )3 08 Ccrit LH L Y Vη µ α= Ω , the aggregates rotate at the same rate as 
the magnetic field.  Above that critical amplitude, the offset between aggregate 
orientation and the field orientation is small and inversely proportional to the square of 
the H-field strength.  Below the critical amplitude, negligible torque is generated on the 
aggregates leading to negligible rotation and subsequently negligible flow.  Above the 
critical amplitude, fluid velocity increases proportionally with field rotation rate.  The 
velocity is independent of the magnetic field strength since further increases in field 
amplitude cannot force the aggregates to rotate any faster than the applied field.  The 
form of the velocity profile is dictated by the concentration gradient, which is dependent 
upon the cross-flow Peclet number, beta, that defines the balance between the magnetic 
body force and hydrodynamic diffusion.  A weaker body force owing to a weaker field 
gradient leads to a flatter velocity profile with less pronounced directional flow within the 
blocked pore.  As such, in order to optimize flow, rapid field rotation, a strong field 
gradient, and a field strength above the critical threshold are all desired. 
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Chapter 5: Displaced Magnetic Field 
5.1 CHANGES TO MODEL EQUATIONS 
In order to improve the model presented in Chapter 4, the assumption that the 
magnetic field source is located at the channel in the region of interest will now be 
eliminated.  This correction is of practical importance as it means that the H-field source 
can now be located outside of the stroke victim’s head.  For a magnetic dipole field 











m m ,  (5.1) 
where M  is the magnetic dipole moment with ( )cosx t= Ωm  and ( )siny t= Ωm .  r is 
the displacement vector between the point of interest and the dipole field source.   
This source displacement from the channel is assumed to occur only in the x 
direction.  Defining 0x  as the displacement of the source from the channel, as shown in 
Figure 5.1, performing a Taylor series expansion, and assuming that 0x x>>  and 






















.  (5.3) 
Setting the characteristic magnetic field strength, H, equal to 304 xπm  yields 
( )2 cosxH H τ=  and ( )sinyH H τ= − . 
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Figure 5.1: Schematic of model system showing particle aggregates, potential flow 
field, and displaced rotating magnetic field source. 
Substituting these new expressions for the x and y components of the dimensionless 
applied magnetic field into equations (4.3-4.5) yields 
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 In order to solve for the magnetically-induced velocity profile, equation (5.4) can 
be analyzed in the same manner as the corresponding equation (4.10) from the previous 
chapter with the same no slip boundary conditions at the channel walls.  The same 
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Solving for the spatially-averaged magnetically-induced velocity gives 
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As such, the pressure gradient and pressure-induced velocity profile are given by 
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5.2 PARTICLE DYNAMICS 
5.2.1 Torque 
Computational simulations of these updated equations were performed in order to 
evaluate the changes to the particle dynamics and resulting flow field with the magnetic 
field source displaced.  As such, the transient torque is plotted in Figure 5.2a with the 
applied magnetic field above, at, and below the critical field strength.  The time-averaged 




Figure 5.2: Dimensionless torque on particle aggregates in the presence of magnetic 
fields a) over time above, at, and below the magnetic field’s critical 
threshold, and b) time-averaged at various magnetic field strengths. 
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The torque generated on the ferro-aggregates with the H-field displaced is 
approximately zero when the field strength is less than the critical value.  When the 
applied magnetic field strength is greater than the threshold strength, the dimensionless 
torque transiently oscillates between about 0.5 and 2 with a dimensionless time period of 
π, or half an aggregate revolution.  The average dimensionless torque is around 1. 
These oscillations in the torque occur because displacing the magnetic field 
source causes a change in the magnetic field being applied at the channel.  The amplitude 
of the x-component of the applied field is now twice that of the y-component. 
Around the critical field strength, the time-averaged dimensionless torque quickly 
transitions between 0 and 1.  The transient behavior of the torque is erratic, even 
switching sign, and thus direction. 
5.2.2 Orientation Angle 
Figure 5.3 tracks the rotation of the aggregates in response to the torque, plotting 
their orientation angle over time, for three different cases: above, at, and below the 
critical magnetic field amplitude.  As with the non-displaced magnetic field source 
analyzed in Chapter 4, when the applied field is weaker than the critical field, aggregate 
rotation is insignificant.  When the applied magnetic field strength is greater than the 
critical H-field strength, however, the aggregates no longer rotate in sync with the field 
source.  Orientation angle does not change linearly from π to –π, but instead deviates 
from linearity in an oscillatory manner in response to the changing torque.  Around the 
threshold magnitude, the aggregates still rotate primarily in one direction, but their 
rotation is chaotic and bears little to no resemblance to the field rotation.   
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Figure 5.3: Orientation angle of the aggregates over dimensionless time for 5Hz 
magnetic fields above, at, and below the critical field strength.   
5.2.3 Offset Angles 
Alternatively, this information can be demonstrated by plotting the difference 
between aggregate orientation and the H-field source orientation over time as shown in 
Figure 5.4.  For magnetic fields much stronger than the critical threshold strength, 
following an initial transience, this pseudo-offset angle oscillates around –π/2.  The 
oscillations are in response to the changing torque.  Due to the displacement of the 
magnetic field source from the channel, the applied magnetic field is no longer oriented 
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in the same direction as the magnetic field source.  As such, aggregate orientation 
initially rapidly transitions from agreement with the H-field source at zero degrees to near 
alignment with the applied field source.  This leaves the magnetic field source 
approximately 90 degrees, or π/2 radians, behind the orientation of the aggregates. 
 
 
Figure 5.4: The difference between aggregate orientation and the magnetic field source 
orientation over time above, at, and below the magnetic field’s critical 
threshold. 
The magnitude of the time-averaged offset angle between the orientation of the 
aggregates and the applied H-field orientation is plotted against the magnetic field 
strength in Figure 5.5 in order to obtain further insight into the particle dynamics.  As 
with the non-displaced magnetic field source, the largest transiently averaged offset 
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angles are obtained for applied H-field strengths near the critical threshold because 
aggregate orientation and offset behave chaotically over time.  Small average offset 
angles are obtained for weak magnetic fields well below the threshold magnitude because 
the aggregates have essentially stopped moving.  Both offset angle and applied magnetic 
field orientation are bound between –π and π, and the average applied H-field orientation 
is zero.  As such, the times when aggregate offset is negative cancel out those when offset 
is positive.  For magnetic field strengths well above the critical magnitude, the offset 
angle, θ, approaches zero for all times following the initial transience.    
 
 
Figure 5.5: The magnitude of the time-averaged offset angle between aggregate 
orientation and the applied magnetic field orientation at various magnetic 
field strengths. 
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5.3 FLUID FLOW 
5.3.1 Magnetically-Induced Velocity Profile 
The aggregate dynamics induce fluid flow within the channel, so the critical field 
strength which plays such an important role in those dynamics is also an essential 
parameter of the fluid velocity profile.  Figure 5.6a plots the dimensionless magnetically-
induced velocity profile across the channel at the critical magnetic field strength for a 
particular cross-flow Peclet number, β, of 75, while Figure 5.6b does the same above the 
magnetic field strength. 
Since the torque changes transiently due to the magnetic field source 
displacement, the magnetically-induced velocity also changes with time.  The spatially-
averaged velocity is actually proportional to the torque on the aggregates.  A negative 
velocity profile is obtained at τ = 2π with the magnetic field near its critical strength 
because the corresponding torque is negative.  Similarly, well above the threshold field 
strength, the torque and magnetically-induced velocity both oscillate transiently with a 
dimensionless time period of π.  As such, both are minimized when the dimensionless 











Figure 5.6: Dimensionless velocity profiles across a blocked channel with β = 75 a) at 
the magnetic field’s critical threshold and b) above the critical magnetic 
field strength. 
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5.3.2 Pressure-Induced and Overall Velocity Profiles 
As noted in Chapter 4, in a blocked channel, a pressure field will develop in 
response to drive fluid flow away from the blockage. The magnetically-induced, 
pressure-induced, and overall dimensionless velocity profiles, Um, Up, and Uy, 
respectively are shown for β = 75 in Figures 5.7a-c. 
The transient magnetically-induced velocity produces a correspondingly transient 
pressure gradient and, therefore, transient pressure-induced velocity. Larger 
magnetically-induced velocities yield larger pressure-induced velocities, so the 
magnitude of Up reaches its maxima and minima at the same times as Um.  Superposition 
of the positive magnetically-induced and negative pressure-induced flow fields yields the 
net flow field for the system.  The fluid flows toward the clot along one wall and returns 
from the occlusion by the other wall in keeping with continuity, which dictates that the 









Figure 5.7: Dimensionless velocity profiles across a blocked channel with β = 75 
showing how the superposition of a) the magnetically-induced velocity 
profile and b) the pressure-induced velocity profile creates c) the overall 
velocity profile for magnetic fields much stronger than the critical threshold. 
5.3.3 Shear and Volume Fraction Profiles 
Based upon the overall velocity profile, the shear rate profile within the blocked 
channel can be obtained from the derivative of the velocity with respect to x.  As shown 
in Figure 5.8, when a typical 7500A/m magnetic field, well above the critical H-field 
strength, rotating at 5Hz, or 10π radians per second, is applied to an occluded channel 
with an average ferroparticle volume fraction of 0.1%, the magnitude of the shear rate is 
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less than that of the rotation rate throughout most of the channel.  Near the channel wall 
closer to the field source, however, the shear surpasses the rotation rate.  Despite the 
small portion of the channel where this happens, this is still notable since the 
ferroparticles are heavily concentrated in that region.  While unimportant for aggregates 
of fixed size, rotation and shear are competing mechanisms by which the ferro-aggregates 
may be broken down.  Figure 5.8 suggests that both mechanisms are important.  Shear 
dominates in the thin layer near the wall, where the ferro-aggregates are most 
concentrated, while rotation dominates everywhere else. 
 
 
Figure 5.8: Dimensionless induced shear and ferroparticle volume fraction profiles 
across a channel with an average volume fraction of 0.1%, under the 
influence of a 7500A/m magnetic field rotating at 5Hz, when τ = π/2.  
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Chapter 6: Aggregates of Variable Size 
6.1 EQUATIONS RELATING SHEAR, LENGTH, AND ASPECT RATIO 
In order to further improve the model presented in Chapter 5, the assumption that 
the aggregates are of fixed size will now be eliminated.  As in practice, the size of the 
aggregates will be dictated by either their rotation or the shear acting on them, whichever 
keeps the aggregates smaller.  Following Bossis (2002) and Gomez-Ramirez (2011), the 
















,  (6.1) 
where pr  is the radius of the individual ferroparticles, fµ  is the relative magnetic 
permeability of the fluid, and pµ  is the relative magnetic permeability of the ferro-
aggregates.  The relative magnetic permeability of the fluid is assumed to be 
approximately equal to 1, while the relative magnetic permeability of the aggregates is 
functionally related to their magnetic susceptibility, Mχ . 
 1p Mµ χ= +   (6.2) 
The magnetic susceptibility relates the applied magnetic field strength to the 
magnetization of the aggregates in a manner similar to equation (3.6). 
 Mm hχ= ,  (6.3) 
 L Tα α= ⋅ +m pp h h , (3.6) 
where Lα  is related to the aspect ratio, ( )( ) ( )
122 3 ln 2 / 1L L a L aα
−
 = −  , and 2Tα =  
[Rocha and Acrivos (1974)]. 
It follows that  
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  (6.6) 
In order to fully describe the size of the aggregates, however, the relationship 
between aggregate diameter, 2a, and aggregate length, 2L, must also be defined.  From 
the analysis of Gomez-Ramirez (2011), pL r  is “roughly proportional” to ( )
2
pa r .  Since
pL r  is equivalent to the number of particles along the major axis of the ellipsoid and 
pa r  is equal to the number of particles along the minor axis of the ellipsoid, this makes 
physical sense.  In response to increased magnetic field strength, aggregate diameter will 
increase slower than aggregate length due to the tendency of the ferroparticles to align 
themselves with the applied magnetic field.  Aggregate diameter is not constant with 
increasing H though. As magnetic field strength increases, the magnetic attractive forces 
increase and ferroparticles can more easily join aggregates without attaching to one end 
or the other.  As such, ( )kp pa r L r=  where k is between 0 and 1.  Setting k to 0.5 gives 
2
pL a r= . 
6.2 FURTHER ADJUSTMENTS TO MODEL EQUATIONS 
Aggregate length variability also affects other parameters of the magnetically-
induced velocity.  Significantly, the characteristic velocity depends upon L.  As such, 
using the non-dimensionalizations from Chapter 3 is no longer practical, and equations 
will now be presented dimensionally.   
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Additionally, the magnitude of the hydrodynamic diffusion of the aggregates, d , 
is defined by the product of the shear and L2 [Davis (1996)]. 
 2Lγ=d   (6.7) 
Aggregate velocity across the channel due to the magnetic field gradient, ug, is 
proportional to the magnetization of the aggregates and, therefore, is roughly proportional 
to the product of the H-field strength and the aspect ratio dependent parameter Lα . 
 g Lu Hα∝   (6.8) 
 Since the balance between gu  and d controls the shape of the concentration 
profile within the channel, the equations relating to the concentration must be updated as 
well.  Equation (3.4), defining the aggregate number density, must be modified to define 
the ferroparticle number density since aggregates are no longer conserved. 
 ( )n n n
t
∂
+ ⋅∇ = ∇⋅ ⋅∇
∂ g
u d  (3.4) 
The number of particles per aggregate, an , can be defined by the ratio of particle number 




=   (6.9) 
Alternatively, an  can be defined with respect to the physical dimensions of the 







= .  (6.10) 
Since n, c, ug, and d are all dependent upon L and, therefore, x but independent of y-
position along the channel, equation (3.4) then becomes   
 g a
a
u c nc c c
t x x x x n x
∂  ∂∂ ∂ ∂ ∂ = − + −   ∂ ∂ ∂ ∂ ∂ ∂   
d d .  (6.11) 
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Additionally, since a, L, n, and Lα  are all functions of x, the equations for the velocity 
profiles must be adjusted.  The magnetically-induced velocity profile becomes 
 ( )2 2 20
0 0




xu H a Ln a Ln x f t
d
µπ α ψ α φ
η
 = − Ω 
 ∫ ∫ ,  (6.12) 
where ( ) ( ) ( ) ( ) ( )2 2, , sin 2 cos 2 sin cos sin 4cosf t t t tφ φ φ φ  Ω = Ω − Ω − Ω   and ψ is being 
used as a variable of integration in place of x. 
6.3 MODEL SYSTEM PARAMETERS AND INITIAL CONDITIONS 
These equations are of a circular nature.  For example, shear defines aggregate 
length, which sets the concentration profiles of the aggregates and ferroparticles, which 
affect the velocity profiles that define the shear.  As such, computational solution of these 
expressions is very useful.  Computational loops can be used to solve the system of 
equations transiently, solving for new values at the current time based upon previous 
values at past times.  For example, the original expression for the shear defines an 
expression for aggregate length, which ultimately defines a new shear at a new time. 
In order for this approach to work, initial conditions must be provided.  These 
initial conditions are listed in Table 6.1.  The dimensional values of the system 







Initial Value in 
Alternate Units 
a aggregate semi-minor axis length 5×10-7 m 500nm 
ϕ aggregate orientation π/2 radians 90° 
β cross-flow Peclet number 75  
mu  magnetically-induced velocity 0 m/s 0 mm/s 
pu  pressure-induced velocity 0 m/s 0 mm/s 








rp ferroparticle radius 5×10-8 m 50 nm 
d channel diameter .003 m 3 mm 
H H-field strength 7500 A/m  
Ω H-field rotation rate 10π rad/s 5 Hz 
η fluid viscosity 4×10-3 Pa∙s  
0µ  magnetic permeability of a vacuum 4π×10-7 N/A2  
fµ  relative magnetic permeability of fluid 1  
Φ average volume fraction of particles 10-3 0.1% 
Table 6.2: Fixed values of various system parameters used for solving the base case. 
6.4 AGGREGATE ORIENTATION 
Computational simulations of the updated equations were performed using the 
preceding system parameters and initial conditions.  Changes to the particle dynamics 
and the resulting flow field were evaluated with aggregate size controlled by rotation and 
shear. 
Figure 6.1 tracks the rotation of the aggregates, plotting their orientation angle 
over time.  Aggregate orientation does not change noticeably depending upon whether 
aggregate size is fixed or not. 
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Figure 6.1: Orientation angle of the aggregates over time for a 7500A/m magnetic field, 
above the critical field strength, rotating at 5Hz. 
6.5 VELOCITY PROFILES 
As shown in Figures 6.2a-c, the magnetically-induced, pressure-induced, and 
overall velocity profiles obtained using the variable aggregate size model appear 
qualitatively similar to those  obtained with aggregate size fixed.  The velocity profiles 
still oscillate transiently with a dimensionless time period of Ωt = π.  Interestingly, 
although the system was computationally solved transiently assuming an initially 
quiescent channel, by the time Ωt equals π/2, the system has reached its pseudo-steady 
state in which the flow field repeats every dimensionless time period. 
For the base case in which a 7500A/m magnetic field rotating at 5Hz is applied to 
a channel with an average ferroparticle volume fraction of 0.1%, the overall flow velocity 
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toward the blockage achieves a maximum value of roughly 3.53mm/s when Ωt equals π/2 
and where x equals 2.9mm.  The return flow velocity away from the blockage obtains its 
maximum magnitude of about 1.35mm/s at the same time where x equals 1mm.   
 
 
Figure 6.2: Velocity profiles across a blocked channel with an average ferroparticle 
volume fraction of 0.1% in the presence of a 7500A/m magnetic field 
rotating at 5Hz showing how the superposition of a) the magnetically-
induced velocity profile and b) the pressure-induced velocity profile creates 
c) the overall velocity profile. 
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6.6 SHEAR, AGGREGATE SIZE, AND VOLUME FRACTION PROFILES 
Since the velocity profiles qualitatively match with those obtained in Chapter 5, it 
follows that the shear profiles are also of similar shape.  As shown in Figure 6.3a, the 
base case of a 7500A/m magnetic field rotating at 5Hz applied to an occluded channel 
with an average ferroparticle volume fraction of 0.1% still yields shear rates that are less 
significant than the rotation rate throughout most of the channel.  Near the channel wall 
closer to the field source, the shear still surpasses the rotation rate.  The ferro-aggregates 
in that region are sheared to lengths that are shorter than the rotationally set maximum as 
shown in Figure 6.3b.   
Figure 6.4 highlights some differences between the fixed and variable aggregate 
size models.  The ratio of the maximum induced shear to the rotation rate is significantly 
decreased by using the variable size model.  Correspondingly, the width of the region 
where shear dominates is smaller, however, this does not mean that the shearing of the 
aggregates is unimportant.  The ferroparticle volume fraction profile is even sharper, 




Figure 6.3: Profiles of a) shear and b) length of the semi-major axis of the aggregates 
across a channel, with an average ferroparticle volume fraction of 0.1%, in 
the presence of a 7500A/m magnetic field rotating at 5Hz when Ωt equals 
π/2 and π. 
 83 
 
Figure 6.4: Profiles of induced shear and particle volume fraction across a blocked 
channel, with an average volume fraction of 0.1%, under the influence of a 
7500A/m magnetic field rotating at 5Hz when Ωt equals π. 
6.7 AVERAGE MAGNETICALLY-INDUCED VELOCITY 
Due to the high shear near the channel wall closer to the magnetic field source, 
the length of the aggregates is not constant in time or space under the base conditions.  
When the aggregates were of fixed length, the average magnetically-induced velocity 
changed proportionally with the rotation rate of the applied magnetic field as suggested 
by the characteristic velocity chosen for the non-dimensionalization in Chapter 3, 
3
cu L d V= Ω Φ . 
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Unfortunately, that characteristic velocity also depended upon aggregate size.  If 
the rotation rate is permitted to control aggregate size with the magnetic field strength 
held constant, increased rotation rate will lead to smaller aggregates until they are broken 
down into individual ferroparticles unable to effectively induce fluid flow.  This is shown 
in Figure 6.5 as the rotation of the magnetic field becomes faster than 10Hz. 
Decreasing rotation rate will also eventually lead to no flow.  As originally 
indicated by the characteristic velocity, no matter how large the aggregates are, if they do 
not rotate, no fluid flow will be induced.  As such, the average magnetically-induced 
velocity must reach a maximum at some intermediate field rotation rate.   
 
Figure 6.5: Average magnetically-induced velocity in a channel with an average particle 
volume fraction of 0.1% under the influence of a 7500A/m magnetic field 
rotating at various frequencies. 
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There are other issues with low rotation rate, however, that relate to aggregate 
size.  The sharp change in the average magnetically-induced velocity between 3.25Hz 
and 3.5Hz depicted in Figure 6.5 is caused by the introduction of the shear as a parameter 
of interest.  As shown in Figure 6.6, for a 7500A/m magnetic field, when the rotation rate 
is 3.25Hz or less, the rotation sets aggregate length everywhere in the channel.  When the 
rotation rate is 3.5Hz or more, shear controls aggregate length near the channel wall 
closer to the magnetic field source.   
 
 
Figure 6.6: Length of the semi-major axis of the aggregates near the wall where shear is 
highest under the influence of a 7500A/m magnetic field rotating at 5Hz and 
3.25 Hz when Ωt equals π/2 and π. 
Assuming a fixed quantity of ferroparticles, or a fixed average volume fraction, as 
the aggregates grow larger the number of aggregates drops.  When the H-field rotation 
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rate is decreased, without sufficient shear to keep aggregate size under control, the 
number of aggregates eventually becomes too few to effectively induce flow.  This is 
reflected in Figure 6.5 as the rotation of the magnetic field becomes slower than 1.5Hz. 
This effect can also occur as the magnetic field strength is increased beyond 
10,000A/m while the rotation rate is held constant at 5Hz as shown in Figure 6.7.   
 
 
Figure 6.7: Average magnetically-induced velocity in a channel with an average particle 
volume fraction of 0.1% under the influence of a 5Hz magnetic field at 
various field strengths. 
Based upon Figures 6.5 and 6.7, it is evident that careful selection of the 
frequency and magnitude of the applied magnetic field is essential to optimizing the 
magnetically-induced flow in occluded vessels. 
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Chapter 7: Transport in a Magnetically-Induced Flow Field 
7.1 INTRODUCTION 
In order to more fully understand the time required for thrombolytic to be 
delivered to a thrombus when the transport has been magnetically-enhanced, 
computational simulations were developed to investigate the convective and diffusive 
transport in an artery. 
A number of assumptions were made.  The reactions of the thrombolytic both 
within the bloodstream and at the thrombus were ignored.  The transient oscillations of 
the induced flow field were also ignored.  Additionally, the initial evolution of the 
ferroparticle concentration profile within the occluded vessel is also ignored.  The 
ferroparticle concentration gradient is assumed to be fixed with respect to both time and 
y-position along the blocked channel length. 
The model geometry was a two-dimensional representation of the last 4.5cm of a 
3mm wide channel leading up to a blockage, like a thrombus.  It did not include the 
neighboring unblocked vessel or the entrance to the occluded vessel.  As such, transport 
through the unblocked vessel and entrance effects at the inlet to the occluded vessel were 
not analyzed. 
7.2 FLOW FIELD 
The steady state flow field was computationally obtained by using COMSOL 
Multiphysics to simultaneously solve the continuity (2.1) and incompressible Navier-
Stokes (2.2) equations.   
 0∇⋅ =u  (2.1) 
 ( ) ( )( )Tptρ ρ µ
∂  + ⋅∇ = ∇⋅ − + ∇ + ∇ +
 ∂
u u u I u u F  (2.2) 
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In the Navier-Stokes equations, the magnetic body couple was treated as an external force 
acting on the fluid continuum.  This force and the inlet velocity at the entrance to the 
model geometry were defined by computational solution of the variable aggregate size 
model presented in Chapter 6 assuming a 7500A/m applied magnetic field rotating at 5Hz 
but with the average particle volume fraction an order of magnitude lower than the base 
case, at 0.01%.  To avoid the transient oscillations in the velocity, the time-averaged 
overall velocity profile, uy, was utilized.  No-slip boundary conditions were applied at the 
channel walls as well as at the thrombus. 
Throughout most of the channel length, the flow field matches the velocity profile 
defined at the inlet, with no flow across the channel. Near the blockage that velocity 
profile is inaccurate, however, as the flow in the positive y-direction on the right side of 
the channel must turn, travel across the channel, and ultimately become the return flow in 
the negative y-direction on the left side of the channel.  This is shown by the streamlines 
in Figure 7.1a.  The y-component of the velocity field is shown in Figure 7.1b.  The 
maximum velocity obtained by the flow heading toward the thrombus is 0.14mm/s, while 
the maximum magnitude of the return flow velocity is -0.07mm/s. 
Although experiments by Pulse Therapeutics demonstrate that a vortex forms near 
the clot, no such unusual flow effects are predicted by this simulation.  This complex 
behavior would be anticipated, however, if the ferroparticle concentration within the 
blocked channel was tracked over time.  As ferroparticles neared the clot, they would be 
transported across the channel following the streamlines.  The particles would 
subsequently be drawn back across the channel due to the magnetic field gradient, and 




Figure 7.1: a) Streamlines and b) the y-component of the overall velocity in an occluded 
vessel acted upon by a 7500A/m magnetic field rotating at 5Hz with the 
ferroparticles accounting for a volume fraction of 0.01%. 
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7.2 THROMBOLYTIC CONCENTRATION 
Computational simulation of the transient evolution of the thrombolytic 
concentration profile within the blocked vessel was subsequently performed using the 
steady state flow field.  In keeping with the diffusion-limited simulations from Chapter 2, 
a thrombolytic diffusion coefficient of 8×10-10m2/s was used.  Boundary conditions of no 
flux of thrombolytic through the channel walls or thrombus were used.  For the initial 
condition, the thrombolytic was assumed to have already penetrated 1cm into the model 
geometry as shown on the left side of Figure 7.2.  The thrombolytic concentration 
everywhere within that first centimeter was assumed to be initially equal to the 
administered concentration.  Figure 7.2 shows the thrombolytic concentration profile in 
the blocked channel as a fraction of its administered concentration every 100 seconds for 
a total of 700s. 
The thrombolytic travels the additional 3.5cm from the initial concentration front 




Figure 7.2: Concentration profiles for the thrombolytic, as a fraction of the administered 
concentration, over time with 100 seconds between images.  
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Chapter 8: Concluding Remarks 
8.1 CONCLUSIONS 
Magnetically-enhanced transport of thrombolytics through occluded vessels is 
possible.  Applying a sufficiently strong magnetic field with a gradient will make 
ferroparticles administered with the thrombolytic aggregate into chains on one side of the 
blocked vessel.  For applied magnetic fields above a critical threshold strength, which can 
be estimated as ( )3 08 Ccrit LH L Y Vη µ α= Ω , the aggregates will rotate at the same rate as 
the magnetic field.  The rotation of these aggregates will induce fluid flow and restore 
convective transport within the clogged vessel if the magnitude and frequency of the 
applied magnetic field are carefully selected to yield aggregates of sufficient size and 
quantity. 
Simulation results predicting thrombolytics reaching a clot 3.5cm into an 
occluded channel, at a concentration comparable to that at which it entered, within five 
minutes, strongly suggest that the magnetically-enhanced transport method invented by 
Pulse Therapeutics would be extremely effective in treating strokes.  Given the inherently 
time-sensitive nature of stroke treatment, this would represent an enormous improvement 
on the current diffusion-limited standard.  It should be noted though that a number of 
assumptions were introduced in Chapter 7 to obtain those results.  Experiments 
conducted by Pulse Therapeutics suggest that, for the simulated occluded vessel size, the 
thrombolytic should reach the clot in five to fifteen minutes. 
Correcting the simulation assumptions will slow the theoretical thrombolytic 
transport or reduce the amount of thrombolytic predicted to reach the clot.  For example, 
accounting for the reaction of the thrombolytic in the bloodstream will slightly decrease 
the amount of thrombolytic theoretically reaching the clot.  Fortunately, tPA’s half-life of 
5 to 10 minutes [Gravanis and Tsirka (2008)] and streptokinase’s half-life of 23 minutes 
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[Baker (2003)] are both longer than the predicted transport time to the simulated clot. As 
such, at least half of the thrombolytic entering the blocked vessel should be able to reach 
the clot within five minutes. 
 Including the initial evolution of the ferroparticle concentration profile within the 
simulated blocked channel and establishing the predicted ferro-aggregate gradient could 
substantially increase the time required for the thrombolytic to reach the clot.  
Realistically, the flow field would not already be at steady state when the thrombolytic 
starts traveling through the blocked vessel.  The ferroparticles also need to be transported 
through the clogged vessel.  In order to induce flow toward the clot in a particular 
location, ferroparticles must be present there.  As such, the region of the occluded 
channel near to the blockage would not experience induced flow until about the same 
time that thrombolytic initially reached that region. 
Even if accurate tracking of the ferroparticles and ferro-aggregates increases the 
theoretical time required for thrombolytic to reach the clot by an entire order of 
magnitude, the magnetically-enhanced transport will still be vastly superior to the current 
standard of diffusion-limited transport.  The magnetically-enhanced transport would still 
carry at least 0.1 percent of the administered thrombolytic to the clot, 3.5cm into the 3mm 
wide occluded vessel, within 50 minutes.  Simulation of the diffusion-limited transport 
predicts that less than 10-4 percent of the administered thrombolytic is delivered to a 
thrombus located a mere 0.5cm into a 3mm wide blocked blood vessel within 2 hours, 
assuming that the blocked vessel branches off from its neighboring unblocked vessel at a 
45° angle. 
Given the magnitude of this improvement, the practical application of 
magnetically-enhanced thrombolytic transport for stroke treatment in hospitals could save 
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an untold number of lives.  Developing guidelines and protocols for the treatment method 
should be a priority. 
8.2 SUGGESTED FUTURE WORK 
The rate of thrombolytic delivery could be better understood and more easily 
predicted if the magnetically-enhanced convective-diffusive transport model, discussed in 
Chapter 7, accounted for the transient evolution of the ferro-aggregate concentration 
profile in the occluded vessel.  Another possible improvement to that model is accounting 
for the reaction of the thrombolytic both in the bloodstream and at the clot.  Transiently 
keeping track of the quantity of thrombolytic actually delivered to the thrombus would 
also be beneficial. 
More fundamentally, the magnetic field source in the model could be permitted to 
rotate in all three spatial dimensions and the corresponding aggregate dynamics could be 
analyzed in 3D.  The effect of the three-dimensional rotation of the aggregates on the 
flow field could then be considered.  The geometry of the occluded vessel could also be 
improved from the current two-dimensional channel into a three-dimensional tube.  
Including the neighboring unblocked vessel in the model geometry would allow for 
analysis of the entrance effects going into the occluded vessel.  The length, diameter, and 
branch angle of the blocked vessel could be treated as system variables as in Chapter 2.  
Additionally, the magnetic field source could be offset from the model geometry in 
different directions in order to further investigate the effect of H-field source position.  
Since aggregate concentration is highest near a vessel wall, the interactions between the 




Appendix A: Nomenclature 
A.1 CHAPTER 2 NOMENCLATURE 
Latin alphabet based 
c concentration (mol/m3; μM) 
D diameter of the occluded vessel (m; mm) 
Dτ,P diffusion coefficient of thrombolytic/plasminogen (m2/s; mm2/hr) 
F external forces (N) 
I identity matrix 
k reaction rate constant 
k’ pseudo-reaction rate constant 
L length of the occluded vessel (m; cm) 
p pressure (Pa) 
P free plasminogen concentration (mol/m3; μM) 
Pb bound plasminogen concentration (mol/m3; μM) 
Q blood flow rate in unblocked vessel (m3/s; mL/min) 
R reaction rate (mol ⋅m-3 ⋅ s-1) 
S streptokinase concentration (mol/m3; μM) 
t time (s) 
T tPA concentration (mol/m3; μM) 
u velocity (m/s; cm/s) 
Greek alphabet based 
δ characteristic clot thickness (m) 
θ angle between the blocked and unblocked vessels (≤ 90°) 
μ viscosity of fluid medium (Pa ⋅ s) 
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ρ density of fluid medium (kg/m3) 
τ thrombolytic concentration (mol/m3) 
Subscripts 
b bound 




1 during first hour following start of administration; during administration 
2+ after first hour following start of drug administration; after administration 
A.2 CHAPTER 3-6 NOMENCLATURE 
Latin alphabet based 
a length of an aggregate’s semi-minor axis (m) 
c ferroparticle number density (particles/m3) 
C ferroparticle number density (dimensionless) 
C# constant of integration 
d channel diameter (m) 
d effective hydrodynamic diffusion vector (m2/s) 
D effective hydrodynamic diffusion (dimensionless) 
e∞ strain rate due to the flow (s-1) 
E∞ strain rate due to the flow (dimensionless) 
f function 
GA anti-symmetric stress tensor (dimensionless) 
GM magnetic torque (dimensionless) 
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 h applied magnetic field (A/m) 
 H applied magnetic field (dimensionless) 
 K rotation matrix 
 L length of an aggregate’s semi-major axis (m) 
M magnetic dipole moment (A ⋅m2) 
 m magnetization of the aggregates (A/m) 
 M magnetization of the aggregates (dimensionless) 
 n aggregate number density (aggregates/m3) 
an   number of particles per aggregate 
 N aggregate number density (dimensionless) 
 p pressure (Pa) 
 P pressure (dimensionless) 
 p director describing aggregate orientation 
 r displacement from magnetic field source (m) 
 rp radius of ferroparticles (m) 
 t time (s) 
 TA anti-symmetric stress tensor 
 TH,M hydrodynamic/magnetic torque (N ⋅m) 
 u velocity (m/s) 
 U velocity (dimensionless) 
 V volume of an aggregate (m3) 
 VP volume of a particle (m3) 
 x position across channel (m) 
0x  distance between the magnetic field source and the channel wall at x=0 
 X position across channel (dimensionless) 
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 XC function of aggregate eccentricity (dimensionless) 
 y position along channel (m) 
 Y position long channel (dimensionless) 
 YC,H functions of aggregate eccentricity (dimensionless) 
Greek alphabet based 
,L Tα  functions defining aggregate magnetization (dimensionless) 
 β ratio relating magnetic body force to hydrodynamic diffusion (dimensionless) 
 ε eccentricity of the aggregates (dimensionless) 
 η viscosity of fluid medium (Pa ⋅ s) 
 θ offset angle between aggregate orientation and applied magnetic field orientation 
0µ  magnetic permeability of a vacuum (N/A2) 
fµ   relative magnetic permeability of fluid (dimensionless) 
pµ   relative magnetic permeability of ferro-aggregates (dimensionless) 
 ρ density of fluid medium (kg/m3) 
 τ time (dimensionless) 
 ϕ orientation angle of the aggregates 
 Φ average volume fraction of particles/aggregates 
Mχ   magnetic susceptibility (dimensionless) 
 Ψ variable of integration 
 ω angular velocity of the aggregates (rad/s) 
 ω∞ angular velocity of the bulk fluid (rad/s) 
 Ω angular velocity of the applied magnetic field (rad/s) 











x across the channel 
y along the channel; in flow direction 
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Appendix B: Functional Parameters of Aggregate Orientation 
The hydrodynamic torque on the aggregates is a function of three different 
eccentricity dependent values: 
 ( ) ( )
1
3 2 24 11 2 1 ln
3 1
CX εε ε ε ε
ε
−
 +  = − − −   −  
,  (B.1) 
 ( ) ( )
1
3 2 24 12 2 1 ln
3 1
CY εε ε ε ε
ε
−
 +  = − − + +   −  
 , (B.2) 
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HY εε ε ε
ε
−
 +  = − + +   −  
.  (B.3) 
 In order to describe the rate of change of the aggregate orientation, a matrix K(p) 
is multiplied by the aggregate orientation rate.  This transformation matrix functions to 
describe the relationship between the fixed spatial Cartesian coordinate system of the 
channel and the coordinate system of the rigid body described by its Euler angles.  It is 
given by  
 ( )
0 cos sin sin
cos 0 sin cos
sin sin sin cos 0
θ θ φ
θ θ φ
θ φ θ φ
− 
 = − 
 − 
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